<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">61798</article-id><article-id pub-id-type="doi">10.7554/eLife.61798</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-202791"><name><surname>Rosenkranz</surname><given-names>Sina C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5228-4266</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202792"><name><surname>Shaposhnykov</surname><given-names>Artem A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6772-6074</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202793"><name><surname>Träger</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202794"><name><surname>Engler</surname><given-names>Jan Broder</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3169-2076</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202795"><name><surname>Witte</surname><given-names>Maarten E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1407-6220</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202796"><name><surname>Roth</surname><given-names>Vanessa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202797"><name><surname>Vieira</surname><given-names>Vanessa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0205-9669</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202798"><name><surname>Paauw</surname><given-names>Nanne</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202799"><name><surname>Bauer</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202800"><name><surname>Schwencke-Westphal</surname><given-names>Celina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5105-4290</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-220092"><name><surname>Schubert</surname><given-names>Charlotte</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2967-4290</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202801"><name><surname>Bal</surname><given-names>Lukas Can</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4731-2311</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202802"><name><surname>Schattling</surname><given-names>Benjamin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8809-9073</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202803"><name><surname>Pless</surname><given-names>Ole</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1468-316X</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202804"><name><surname>van Horssen</surname><given-names>Jack</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4078-7402</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108807"><name><surname>Freichel</surname><given-names>Marc</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1387-2636</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-19825"><name><surname>Friese</surname><given-names>Manuel A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6380-2420</contrib-id><email>manuel.friese@zmnh.uni-hamburg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf</institution><addr-line><named-content content-type="city">Hamburg</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution>Department of Pathology, Amsterdam UMC, MS Center Amsterdam, Amsterdam Neuroscience</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff3"><label>3</label><institution>Department of Molecular Cell Biology and Immunology, Amsterdam UMC, MS Center Amsterdam, Amsterdam Neuroscience</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff4"><label>4</label><institution>Fraunhofer ITMP ScreeningPort</institution><addr-line><named-content content-type="city">Hamburg</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution>Institute of Pharmacology, Heidelberg University</institution><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Harvey</surname><given-names>Brandon K</given-names></name><role>Reviewing Editor</role><aff><institution>NIDA/NIH</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution>Indian Institute of Science Education and Research (IISER)</institution><country>India</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>10</day><month>02</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e61798</elocation-id><history><date date-type="received" iso-8601-date="2020-08-05"><day>05</day><month>08</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-02-10"><day>10</day><month>02</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Rosenkranz et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Rosenkranz et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-61798-v3.pdf"/><abstract><p>While transcripts of neuronal mitochondrial genes are strongly suppressed in central nervous system inflammation, it is unknown whether this results in mitochondrial dysfunction and whether an increase of mitochondrial function can rescue neurodegeneration. Here, we show that predominantly genes of the electron transport chain are suppressed in inflamed mouse neurons, resulting in impaired mitochondrial complex IV activity. This was associated with post-translational inactivation of the transcriptional co-regulator proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). In mice, neuronal overexpression of <italic>Ppargc1a</italic>, which encodes for PGC-1α, led to increased numbers of mitochondria, complex IV activity, and maximum respiratory capacity. Moreover, <italic>Ppargc1a</italic>-overexpressing neurons showed a higher mitochondrial membrane potential that related to an improved calcium buffering capacity. Accordingly, neuronal deletion of <italic>Ppargc1a</italic> aggravated neurodegeneration during experimental autoimmune encephalomyelitis, while neuronal overexpression of <italic>Ppargc1a</italic> ameliorated it. Our study provides systemic insights into mitochondrial dysfunction in neurons during inflammation and commends elevation of mitochondrial activity as a promising neuroprotective strategy.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Multiple sclerosis is a life-long neurological condition that typically begins when people are in their twenties or thirties. Symptoms vary between individuals, and within a single individual over time, but can include difficulties with vision, balance, movement and thinking. These occur because the immune system of people with multiple sclerosis attacks the brain and spinal cord. This immune assault damages neurons and can eventually cause them to die. But exactly how this happens is unclear, and there are no drugs available that can prevent it.</p><p>One idea is that the immune attack in multiple sclerosis damages neurons by disrupting structures inside them called mitochondria. These cellular ‘organs’, or organelles, produce the energy that all cells need to function correctly. If the mitochondria fail to generate enough energy, the cells can die. And because neurons are very active cells with high energy demands, they are particularly vulnerable to the effects of mitochondrial damage.</p><p>By studying a mouse version of multiple sclerosis, Rosenkranz et al. now show that mitochondria in the neurons of affected animals are less active than those of healthy control mice. This is because the genes inside mitochondria that enable the organelles to produce energy are less active in the multiple sclerosis mice. Most of these genes that determine mitochondrial activity and energy production are under the control of a single master gene called PGC-1alpha. Rosenkranz et al. showed that boosting the activity of this gene — by introducing extra copies of it into neurons — increases mitochondrial activity in mice. It also makes the animals more resistant to the effects of multiple sclerosis.</p><p>Boosting the activity of mitochondria in neurons could thus be a worthwhile therapeutic strategy to investigate for multiple sclerosis. Future studies should examine whether drugs that activate PGC-1alpha, for example, could help prevent neuronal death and the resulting symptoms of multiple sclerosis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>multiple sclerosis</kwd><kwd>EAE</kwd><kwd>mitochondria</kwd><kwd>neuroprotection</kwd><kwd>Ppargc1a</kwd><kwd>oxidative phosphorylation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008384</institution-id><institution>Stifterverband</institution></institution-wrap></funding-source><award-id>Clinician-Scientist Fellowship</award-id><principal-award-recipient><name><surname>Rosenkranz</surname><given-names>Sina C</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Gemeinnützige Hertie-Stiftung</institution></institution-wrap></funding-source><award-id>Hertie Network of Excellence in Clinical Neuroscience</award-id><principal-award-recipient><name><surname>Rosenkranz</surname><given-names>Sina C</given-names></name><name><surname>Engler</surname><given-names>Jan Broder</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>FR1638/3-1</award-id><principal-award-recipient><name><surname>Freichel</surname><given-names>Marc</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>FR1638/3-2</award-id><principal-award-recipient><name><surname>Freichel</surname><given-names>Marc</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>FR1720/9-1</award-id><principal-award-recipient><name><surname>Friese</surname><given-names>Manuel A</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>FR1720/9-2</award-id><principal-award-recipient><name><surname>Friese</surname><given-names>Manuel A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Inducing neuronal mitochondrial activity during central nervous system inflammation counteracts inflammation-induced neuronal electron transport chain deficiency and calcium toxicity, thereby protecting against neuronal loss in a multiple sclerosis mouse model.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) and the most frequent non-traumatic cause of neurological impairment during early adulthood. Neuronal loss occurs already from disease onset and correlates best with irreversible disability in MS patients (<xref ref-type="bibr" rid="bib14">Fisher et al., 2008</xref>; <xref ref-type="bibr" rid="bib15">Fisniku et al., 2008</xref>; <xref ref-type="bibr" rid="bib61">Tallantyre et al., 2010</xref>). While there has been substantial progress in the understanding and treatment of the immune response, the pathogenesis of concurrent neuronal damage is incompletely understood. Recently, two drugs, ocrelizumab and siponimod, have been licensed for the treatment of progressive MS patients; however, their mode of action relies on immune regulation (<xref ref-type="bibr" rid="bib26">Kappos et al., 2018</xref>; <xref ref-type="bibr" rid="bib38">Montalban et al., 2017</xref>). Since there are currently no therapies available to counteract the progression of neurodegeneration in MS patients (<xref ref-type="bibr" rid="bib9">Dendrou et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Feinstein et al., 2015</xref>) and repurposing of drugs to directly target neurodegeneration in MS has been disappointing (<xref ref-type="bibr" rid="bib6">Chataway et al., 2020</xref>), a better understanding of the molecular processes that determine neuronal cell loss in MS is urgently needed.</p><p>Neuronal loss in MS and its animal model, experimental autoimmune encephalomyelitis (EAE), has been associated with enhanced production of reactive oxygen and nitrogen species by immune cells and with increased iron accumulation in the gray matter (<xref ref-type="bibr" rid="bib60">Stephenson et al., 2014</xref>). Both processes can lead to damage of neuronal mitochondria with subsequent metabolic failure (<xref ref-type="bibr" rid="bib5">Campbell et al., 2011</xref>). Moreover, disruption of neuronal ion homeostasis (<xref ref-type="bibr" rid="bib7">Craner et al., 2004</xref>; <xref ref-type="bibr" rid="bib19">Friese et al., 2014</xref>) and aggregation of neuronal proteins (<xref ref-type="bibr" rid="bib57">Schattling et al., 2019</xref>) consume high amounts of energy that might further drive neuroaxonal injury. Furthermore, excessive activation of calcium-dependent processes and neuronal calcium overload seems to be another important component of neuronal injury (<xref ref-type="bibr" rid="bib18">Friese et al., 2007</xref>; <xref ref-type="bibr" rid="bib56">Schattling et al., 2012</xref>; <xref ref-type="bibr" rid="bib65">Witte et al., 2019</xref>). While identifying druggable targets that specifically induce neuronal resilience has been extremely difficult due to insufficient insights into key modulators, mitochondria could serve as an important hub as they are pivotal for both energy production and calcium homeostasis (<xref ref-type="bibr" rid="bib62">Vafai and Mootha, 2012</xref>).</p><p>Mitochondria usually have a high calcium buffering capacity, which is driven by their negative membrane potential that is generated by the activity of oxidative phosphorylation (<xref ref-type="bibr" rid="bib25">Kann and Kovács, 2007</xref>; <xref ref-type="bibr" rid="bib71">Zorova et al., 2018</xref>). However, overload of mitochondria with calcium as a consequence of CNS inflammation can result in inappropriate activation of the mitochondrial permeability transition pore (PTP) with subsequent mitochondrial swelling and cell death (<xref ref-type="bibr" rid="bib20">Giorgi et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Rizzuto et al., 2012</xref>), which is one of the neuropathological hallmarks in neurons during EAE (<xref ref-type="bibr" rid="bib43">Nikić et al., 2011</xref>). Inhibiting the mitochondrial matrix protein cyclophilin D, a regulator of the PTP can partially counteract this dysregulation (<xref ref-type="bibr" rid="bib16">Forte et al., 2007</xref>). Additionally, to counteract ion imbalance, a higher activity of ATP-dependent ion pumps would be required. However, postmortem studies of MS patients’ CNS tissue revealed a compromised neuronal ATP production by oxidative phosphorylation as decreased mitochondria complex IV activity in demyelinated axons and neurons was detected (<xref ref-type="bibr" rid="bib5">Campbell et al., 2011</xref>; <xref ref-type="bibr" rid="bib36">Mahad et al., 2009</xref>). Similarly, mitochondrial gene expression is suppressed in motor neurons of the spinal cord in EAE mice (<xref ref-type="bibr" rid="bib57">Schattling et al., 2019</xref>), further supporting a comprised mitochondrial function during CNS inflammation.</p><p>Thus, excess neuroaxonal calcium, together with mitochondrial dysfunction, has been postulated to trigger neuroaxonal injury observed in MS and EAE. This would be predicted to lead to elevated levels of calcium within neuronal and axonal mitochondria, further perpetuating mitochondrial dysfunction and neuronal injury. However, it is currently unknown whether interventions that increase mitochondrial energy production in neurons can rescue neurodegeneration during CNS inflammation.</p><p>Here, we discovered by an unsupervised survey of neuronal gene expression during CNS inflammation that genes involved in the electron transport chain (ETC), especially in complex I and IV, are repressed in motor neurons. While this is not accompanied by a decrease of mitochondrial numbers in motor neuronal somata, we detected a decrease in neuronal mitochondrial complex IV activity. This implies a lower activity of neuronal mitochondria during EAE, and we were able to associate that with a post-translational inactivation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), one of the master regulators of mitochondrial numbers and function. Notably, neuronal overexpression of <italic>Ppargc1a</italic>, which encodes for PGC-1α, led to an increase of mitochondrial activity, especially in complex IV activity and substantially elevated calcium buffering capacity. Subjecting these mice to EAE resulted in a significantly better recovery from clinical disability in comparison to wild-type controls. Together, induction of neuronal mitochondrial activity commends as a promising therapeutic approach to counteract inflammation-induced neurodegeneration.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Impaired neuronal oxidative phosphorylation in inflamed spinal cords</title><p>Since we have previously discovered that mitochondrial gene transcripts are markedly suppressed in motor neurons during CNS inflammation in the EAE model (<xref ref-type="bibr" rid="bib57">Schattling et al., 2019</xref>), we first investigated whether unifying biological processes are dysregulated. Therefore, we derived a gene expression signature of motor neurons in spinal cord during CNS inflammation (<xref ref-type="bibr" rid="bib57">Schattling et al., 2019</xref>) and tested for gene set enrichment of biological process gene ontology (GO) terms. While the majority of terms was enriched during inflammation, only a confined group of 29 terms showed strong de-enrichment (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, dashed line) and was dominated by terms representing mitochondrial function (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). A recurring theme was the suppression of the ETC (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Suppression of gene transcripts that are involved in the ETC, which is the key mechanism of oxidative phosphorylation, can either result in reduced number of mitochondria or an impairment of mitochondrial function. Therefore, we quantified mitochondria content in the soma of motor neurons in EAE mice at the chronic stage in comparison to healthy control mice, but did not detect any difference in mitochondria area normalized to neuronal size (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). However, we detected a tendency towards an increase in overall numbers of motor neuronal mitochondria (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>) that was based on an increased size of the neuronal cell body during EAE (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). By contrast, the size of mitochondria did not differ in motor neurons of healthy and EAE mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Reduced activity of oxidative phosphorylation in spinal cord neurons during experimental autoimmune encephalomyelitis (EAE).</title><p>(<bold>A</bold>) Gene set enrichment analysis (GSEA) of biological process gene ontology (GO) terms in motor neurons during central nervous system inflammation in the EAE model. Dashed line indicates 29 de-enriched terms. (<bold>B</bold>) Top 15 de-enriched GO terms with normalized enrichment score. (<bold>C</bold>) GSEA plot of the de-enriched term ‘GO:0022900 electron transport chain’. (<bold>D</bold>) Transmission electron microscopy (TEM) analysis of motor neuronal mitochondrial content normalized to size of healthy (n = 3) and chronic EAE (n = 3) mice (2–3 cells per mice). Bars show mean values ± s.e.m. (<bold>E</bold>) TEM analysis of motor neuronal size of healthy (n = 3) and chronic EAE (n = 3) mice (2–3 cells per mice). Bars show mean values ± s.e.m. (<bold>F</bold>) Representative images of cytochrome <italic>c</italic> oxidase (COX) histochemistry of cervical spinal cord sections of healthy, acute, and chronic EAE mice. Scale bar: 250 µm. (<bold>G</bold>) Quantification of COX histochemistry of cervical spinal cord gray matter (GM) and ventral horn (VH) of healthy (n = 5), acute (n = 3), and chronic (n = 5) EAE mice (2–3 stainings per mice) normalized to HuC/HuD-positive neurons. Bars show mean values ± s.e.m. Statistical analysis in <bold>D</bold> and <bold>E</bold> was performed by unpaired, two-tailed Student’s t-test, and in <bold>G</bold> by one-way ANOVA following Tukey’s post-hoc test for multiple comparisons. *p&lt;0.05, ****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61798-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Reduced numbers of neurons and complex IV activity in spinal cord neurons during experimental autoimmune encephalomyelitis (EAE).</title><p>(<bold>A</bold>) Representative transmission electron microscopy (TEM) images and corresponding magnifications of cervical spinal cord motor neurons of healthy and chronic experimental autoimmune encephalomyelitis (EAE) mice. Scale bar 5 µm. (<bold>B</bold>) Quantification of TEM analysis of motor neuronal mitochondrial numbers of healthy (n = 3) and chronic EAE (n = 3) mice (2–3 cells per mice). Bars show mean values ± s.e.m. (<bold>C</bold>) Quantification of TEM analysis of motor neuronal mitochondrial size of healthy (n = 3) and chronic EAE (n = 3) mice (2–3 cells per mice). Bars show mean values ± s.e.m. (<bold>D</bold>) Quantification of cytochrome <italic>c</italic> oxidase (COX) histochemistry of cervical spinal cord gray matter (GM) and ventral horn (VH) of healthy (n = 5), acute (n = 3), and chronic (n = 5) EAE mice (2–3 stainings per mice). Bars show mean values ± s.e.m. (<bold>E</bold>) Analysis of immunohistochemical stainings of HuC/HuD-positive neurons in cervical spinal cord GM or VH of healthy (n = 5), acute (n = 3), and chronic (n = 5) EAE mice. Bars show mean values ± s.e.m. Statistical analysis in <bold>B</bold> and <bold>C</bold> was performed by unpaired, two-tailed Student’s t-test, and in <bold>D</bold> and <bold>E</bold> by one-way ANOVA following Tukey’s post-hoc test for multiple comparisons. *p&lt;0.05, ****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61798-fig1-figsupp1-v3.tif"/></fig></fig-group><p>Dismissing differences in mitochondrial content, we reasoned that downregulation of ETC transcripts could result in a compromised oxidative phosphorylation activity. By analyzing COX histochemistry that represents complex IV activity, we detected a significant decrease in absolute neuronal complex IV activity in the entire gray matter and ventral horn of acute EAE animals (day 15 post immunization) and in chronic EAE animals (day 30 post immunization) in comparison to healthy control mice (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Normalization to HuC/HuD-positive neurons revealed that the reduced complex IV activity at day 30 was partly driven by neuronal loss, whereas at day 15 the reduced complex IV activity was independent of neuronal numbers (<xref ref-type="fig" rid="fig1">Figure 1G</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D–E</xref>).</p></sec><sec id="s2-2"><title>Inactivation of PGC-1α contributes to mitochondrial dysfunction in CNS inflammation</title><p>Next we interrogated whether a unifying mechanism can explain the inflammation-induced downregulation of gene transcripts that are involved in ETC with consecutively impaired complex IV activity in neurons at the acute stage of EAE. Notably, we detected that many of the genes that drive the downregulation of the ETC theme are usually induced by the transcriptional coactivator <italic>Ppargc1a</italic> (<xref ref-type="bibr" rid="bib35">Lucas et al., 2014</xref>; <xref ref-type="bibr" rid="bib50">Puigserver et al., 1998</xref>; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Consequently, we asked whether <italic>Ppargc1a</italic> could be the sought-after unifying factor that is functionally disturbed. Motor neuronal <italic>Ppargc1a</italic> expression itself was not altered in our previously published dataset comparing acute EAE to controls (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). After confirming this result by an additional translating ribosome affinity purification of motor neuronal transcripts followed by <italic>Ppargc1a</italic> qPCR (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) and immunoblot of PGC-1α of the cervical spinal cord of EAE and healthy mice (<xref ref-type="fig" rid="fig2">Figure 2D, E</xref>), we concluded that transcriptional or translational <italic>Ppargc1a</italic>/PGC-1α regulation cannot be the explanation of the observed ETC downregulation.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Inactivation of proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) in spinal cord neurons during experimental autoimmune encephalomyelitis (EAE).</title><p>(<bold>A</bold>) Heatmap of genes driving the de-enrichment of ‘GO:0022900 electron transport chain’. Heatmap is annotated for electron transport chain complexes and target genes induced by the transcription factor <italic>Ppargc1a</italic> (<xref ref-type="bibr" rid="bib35">Lucas et al., 2014</xref>). (<bold>B</bold>) Normalized RNA-seq expression of <italic>Ppargc1a</italic> in healthy (n = 5) and acute EAE (n = 5) motor neurons. Bars show mean values ± s.e.m. (<bold>C</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> to <italic>Tbp</italic> in healthy (n = 3) and acute EAE (n = 3) motor neurons. Bars show mean values ± s.e.m. (<bold>D</bold>) Quantification of PGC-1α protein in cervical spinal cords of healthy (n = 5) and acute (n = 5) EAE mice. Each sample was normalized to its β-actin. Bars show mean values ± s.e.m. (<bold>E</bold>) Representative immunoblots of PGC-1α, phosphorylated PGC-1αS570 (pPGC-1α), and corresponding β-actin of cervical spinal cords of healthy and acute EAE mice. (<bold>F</bold>) Quantification of phosphorylated PGC-1αS570 (pPGC-1α) in relation to PGC-1α total protein in cervical spinal cords of healthy (n = 5) and acute (n = 5) EAE mice. Each sample was normalized to its β-actin. Bars show mean values ± s.e.m. Statistical analysis in <bold>B</bold> and <bold>C</bold> was performed by unpaired, two-tailed Student’s t-test, and in <bold>D</bold> and <bold>F</bold> by unpaired, two-tailed Mann–Whitney test; *p&lt;0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61798-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Representative immunoblots of phosphorylated PGC-1αS570 (proliferator-activated receptor gamma coactivator 1-alpha [pPGC-1α]) of cervical spinal cords of healthy wild-type mice with and without prior treatment of lambda protein phosphatase for validation of the pPGC-1αS570 antibody.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61798-fig2-figsupp1-v3.tif"/></fig></fig-group><p>Besides quantity, PGC-1α can be post-translationally inactivated by phosphorylation at serine 570 (<xref ref-type="bibr" rid="bib31">Li et al., 2007</xref>; <xref ref-type="bibr" rid="bib66">Xiong et al., 2010</xref>), thereby preventing the recruitment of PGC-1α to its regulated promoters, which we tested next. After validation of phosphorylation specificity of the pPGC-1αS570 antibody (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), we detected a significant increase in phosphorylated-serine570 PGC-1α in spinal cords of acute EAE mice in comparison to healthy control mice (<xref ref-type="fig" rid="fig2">Figure 2E, F</xref>). Thus, we concluded that due to the phosphorylation of PGC-1α during acute stage of EAE that is associated with downregulation of its target gene transcripts and compromised mitochondrial function, <italic>Ppargc1a</italic> could be a potential target to rescue mitochondrial function in EAE-affected motor neurons.</p></sec><sec id="s2-3"><title>Neuronal <italic>Ppargc1a </italic>induction augments mitochondrial function</title><p>Next, we reasoned that elevating neuronal <italic>Ppargc1a</italic> could restore mitochondrial function and serve as a strategy to improve neuronal resilience in CNS inflammation. We utilized transgenic mice with a neuron-specific overexpression of <italic>Ppargc1a</italic> driven under the <italic>Thy1</italic> promoter (Thy1-Ppargc1a) (<xref ref-type="bibr" rid="bib41">Mudò et al., 2012</xref>), which is expressed in mature neurons (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). We could not observe any differences in the health status of these mice. We made sure that elevated transgenic DNA copies of <italic>Ppargc1a</italic> in neurons (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>) resulted in elevated mRNA expression of <italic>Ppargc1a</italic> in cortex, hippocampus, and spinal cord as well as in cortical and hippocampal primary neurons of Thy1-Ppargc1a mice in comparison to wild-type mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C–D</xref>). Additionally, we revealed that Thy1-Ppargc1a mice showed an increase of <italic>Ppargc1a-</italic>dependent transcriptional targets in primary neurons (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E–F</xref>) and <italic>cytochrome c oxidase subunit 4</italic> (<italic>Cox4i1</italic>) and <italic>citrate synthase</italic> (<italic>Cs</italic>) in CNS tissue (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G–I</xref>). Increased mRNA level led to a corresponding increase in protein amount of PGC-1α in primary neurons (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1J</xref>) and spinal cord, which we confirmed by staining for the transgenically fused FLAG-tag (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1K</xref>). Besides Cox4i1, in primary hippocampal neurons, <italic>Ppargc1a</italic> overexpression induced 11 of the 17 <italic>Ppargc1a</italic> regulated ETC genes, which were downregulated in EAE (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Accordingly, neuronal <italic>Ppargc1a</italic> overexpression resulted in increased mitochondrial content in primary neurons (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) and CNS tissue (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Neuronal overexpression of <italic>Ppargc1a</italic> increases neuronal mitochondrial activity.</title><p>(<bold>A</bold>) Relative qPCR mRNA expression in hippocampal primary neuronal cultures (hPNC) (DIV14) of wild-type (n = 4) and Thy1-Ppargc1<italic>a</italic> (n = 4) mice of <italic>Ppargc1a</italic>-regulated electron transport chain genes that were detected to be downregulated during experimental autoimmune encephalomyelitis. Bars show mean values ± s.e.m. (<bold>B</bold>) Mitochondrial DNA copy numbers (mtDNA) relative to diploid nuclear chromosomal DNA (nDNA) in hPNC (DIV14) of wild-type (n = 3) and Thy1-Ppargc1<italic>a</italic> (n = 3) mice. Bars show mean values ± s.e.m. (<bold>C</bold>) mtDNA relative to nDNA in muscle, liver, hippocampus (Hip), cortex, and cervical spinal cord (SC) of wild-type (n = 3) and Thy1-Ppargc1<italic>a</italic> (n = 3) mice. Bars show mean values ± s.e.m. (<bold>D</bold>) Representative images and quantification of cytochrome <italic>c</italic> oxidase (COX) histochemistry of cervical spinal cord gray matter (GM) or ventral horn (VH) of wild-type (n = 5) and Thy1-Ppargc1<italic>a</italic> (n = 6) mice (2–3 stainings per mice) normalized to neuronal nuclei (NeuN)-positive neurons. Bars show mean values ± s.e.m. Scale bar 250 µm. (<bold>E</bold>) Profile and quantification of oxygen consumption rate in hPNC (DIV14) of wild-type (n = 4) and Thy1-Ppargc1<italic>a</italic> (n = 4) mice. Yellow: basal respiration (Basal); blue: ATP-dependent respiration (ATP dependent); orange: maximal respiratory capacity (Max); green: non-mitochondrial respiration (NMR). Bars show mean values ± s.e.m. (<bold>F</bold>) Representative images of hPNC and mean fluorescence intensity quantification of tetramethylrhodamin-ethylester mitochondrial membrane potential assay of hPNC (DIV14) and cortical primary neuronal culture of wild-type (n = 3) and Thy1-Ppargc1<italic>a</italic> (n = 3) mice (five cells per culture). FCCP(carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone) was used as ionophore uncoupler of oxidative phosphorylation. Bars show mean values ± s.e.m. Scale bar: 10 µm. Statistical analysis in <bold>A</bold> was performed by unpaired, one-tailed Student’s t-test, and in <bold>B–E</bold> by unpaired, two-tailed Student’s t-test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Analysis of oxygen consumption rate in primary neurons of Thy1-Ppargc1a mice.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-61798-fig3-data1-v3.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61798-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Neuronal <italic>Ppargc1a</italic> and <italic>Ppargc1a</italic>-dependent target genes are increased in Thy1-Ppargc1a mice.</title><p>(<bold>A</bold>) Relative qPCR mRNA expression of <italic>Thy-1</italic> to <italic>Tbp</italic> in hippocampal primary neuronal culture (hPNC) and cortical primary neuronal cultures (cPNC) (DIV14) of wild-type (n = 6 per group) mice. Bars show mean values ± s.e.m. (<bold>B</bold>) Relative diploid nuclear chromosomal DNA copy numbers of <italic>Ppargc1a</italic> in tail biopsy of wild-type (n = 9) and Thy1-Ppargc1a (n = 16) mice. Bars show mean values ± s.e.m. (<bold>C</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> in hippocampus (Hip), cortex, and cervical spinal cord (SC) of wild-type (n = 5) and Thy1-Ppargc1a (n = 4) mice. Bars show mean values ± s.e.m. (<bold>D</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> in hPNC and cPNC (DIV14) of wild-type (n = 3) and Thy1-Ppargc1a (n = 3) mice. Bars show mean values ± s.e.m. (<bold>E</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> target genes in hPNC (DIV14) of wild-type (n = 3) and Thy1-Ppargc1a (n = 3) mice. Bars show mean values ± s.e.m. (<bold>F</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> target genes in cPNC (DIV14) of wild-type (n = 3) and Thy1-Ppargc1a (n = 3) mice. Bars show mean values ± s.e.m. (<bold>G</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> target genes in hippocampus of wild-type (n = 5) and Thy1-Ppargc1a (n = 4) mice. Bars show mean values ± s.e.m. (<bold>H</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> target genes in cortex of wild-type (n = 5) and Thy1-Ppargc1a (n = 4) mice. Bars show mean values ± s.e.m. (<bold>I</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> target genes in cervical spinal cord of wild-type (n = 5) and Thy1-Ppargc1a (n = 5) mice. Bars show mean values ± s.e.m. (<bold>J</bold>) Representative immunocytochemical staining of proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) in cPNC (DIV14) of wild-type and Thy1-Ppargc1a mice. Co-stainings for microtubule-associated protein 2 (Map2) and 4′,6-diamidino-2-phenylindole (DAPI). Scale bar 10 µm. (<bold>K</bold>) Representative immunohistochemical staining of PGC-1α in spinal cord of wild-type and Thy1-Ppargc1a mice. Co-stainings for neuronal nuclei (NeuN), FLAG, and DAPI. Scale bar 20 µm. (<bold>L</bold>) Mean fluorescence intensity (MFI) quantification of calcein of hPNC (DIV14) of wild-type (n = 1) and Thy1-Ppargc1a (n = 1) mice (three wells per culture) to determine cell viability. Bars show mean values ± s.e.m. Statistical analysis in <bold>C</bold> and <bold>D</bold> was performed by unpaired, one-tailed Student’s t-test, and in <bold>B</bold>, <bold>E–I</bold>, and <bold>L</bold> by unpaired, two-tailed Student’s t-test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61798-fig3-figsupp1-v3.tif"/></fig></fig-group><p>To determine the mitochondrial activity in these mice, we analyzed whether <italic>Ppargc1a</italic>-mediated <italic>Cox4i1</italic> induction resulted in increased complex IV activity. We detected an elevated complex IV activity in the gray matter and ventral horn of Thy1-Ppargc1a mice, which was not due to a higher number of NeuN-positive neurons (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Metabolically, primary neurons of Thy1-Ppargc1a mice showed an elevated oxygen consumption rate and maximum respiratory capacity (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>), which was independent of neuronal numbers (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1L</xref>). In concordance with higher activity of oxidative phosphorylation, primary neurons of Thy1-Ppargc1a mice retained higher tetramethylrhodamin-ethylester (TMRE) fluorescence intensity than wild-type controls, representing a hyperpolarized mitochondrial membrane potential (<xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p></sec><sec id="s2-4"><title>Induction of neuronal <italic>Ppargc1a</italic> improves neuronal calcium buffering capacity</title><p>As CNS inflammation results in substantial neuronal calcium influx (<xref ref-type="bibr" rid="bib65">Witte et al., 2019</xref>) leading to neurodegeneration, which could potentially be buffered by mitochondria, we next asked whether increased neuronal mitochondrial activity and membrane potential in Thy1-Ppargc1a neurons could alleviate toxic calcium levels. By analyzing spontaneously active cortical primary neuronal cultures (cPNC) transduced with the virally encoded calcium indicator GCaMP6f (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), we recorded a significantly faster clearance of intracellular calcium concentrations and decreased amount of mean calcium in spontaneously active Thy1-Ppargc1a primary neurons in comparison to wild-type control neurons, whereas the amplitude and number of calcium transients did not differ (<xref ref-type="fig" rid="fig4">Figure 4B, C</xref>). The results were confirmed with a chemical calcium indicator (<xref ref-type="fig" rid="fig4">Figure 4D</xref> and <xref ref-type="video" rid="video1">Video 1</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Neuronal overexpression of <italic>Ppargc1a</italic> improves neuronal calcium buffering.</title><p>(<bold>A</bold>) Experimental approach for analysis of Ca<sup>2+</sup> signaling. GCamp6f fluorescence was recorded for 10 minutes in spontaneously active cortical primary neuronal culture (cPNC) (DIV15) prior to ionomycin application used for signal normalization. (<bold>B</bold>) Representative cytosolic calcium transients of GCaMP6f-transduced spontaneously active cPNC (DIV15) of wild-type and Thy1-Ppargc1<italic>a</italic> mice normalized to fluorescence of cytosolic calcium-saturated conditions (Fmax). (<bold>C</bold>) Quantification of calcium transient decay constant Tau (T) as an indicator of cytosolic calcium clearance time, calcium transient amplitude (A), mean cytosolic calcium signal intensity and of the number of cytosolic calcium transients presented as firing rate of GCaMP6f-transduced cPNC (DIV15) of wild-type (n = 74 cells from three different mice) and Thy1-Ppargc1a (n = 51 cells from three different mice). 478s of the recorded trace were analysed. Bars show mean values ± s.e.m. (<bold>D</bold>) Representative cytosolic calcium trace of Fluo-4-stained cPNC (DIV14–16) of wild-type and Thy1-Ppargc1a mice. Statistical analysis in <bold>C</bold> was performed by unpaired, two-tailed Student’s t-test. **p&lt;0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61798-fig4-v3.tif"/></fig><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-61798-video1.mp4"><label>Video 1.</label><caption><title>Representative video of calcium transients of Fluo4 stained cortical primary neuronal culture (DIV15) of Thy1-Ppargc1a (left) and wild-type (right) mice.</title><p>Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis.</p></caption></media></sec><sec id="s2-5"><title>Elevated neuronal mitochondrial activity ameliorates neurodegeneration in CNS inflammation</title><p>As we assumed that inactivation of neuronal <italic>Ppargc1a</italic> during CNS inflammation aggravates mitochondrial dysfunction and spurs neuronal vulnerability, we first tested whether this hypothesis holds true in <italic>Ppargc1a</italic>-deficient neurons. We used <italic>Ppargc1a<sup>flx/flx</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic> mice to specifically delete <italic>Ppargc1a</italic> in neurons as <italic>Eno2</italic> is widely expressed in neurons (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Although <italic>Eno2</italic> expression is also present by immune cells (<xref ref-type="bibr" rid="bib23">Heng et al., 2008</xref>), we could exclude <italic>Ppargc1a</italic> expression in immune cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>, <xref ref-type="bibr" rid="bib23">Heng et al., 2008</xref>), therefore securing that <italic>Ppargc1a<sup>flx/flx</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic> mice will not result in altered immune responses. Neuronal deletion of <italic>Ppargc1a</italic> resulted in decreased <italic>Ppargc1a</italic> mRNA levels (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>) and <italic>Ppargc1a</italic> -regulated downstream targets in hippocampus (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>), cortex (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>), and spinal cord (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>). Consequently, neuron-specific <italic>Ppargc1a</italic> knockout mice (<italic>Ppargc1a<sup>flx/flx</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic>) showed a more severe EAE disease course (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>) and by using NeuN-staining an increased neuronal loss in the gray matter and ventral horn in comparison to <italic>Ppargc1a<sup>flx/flx</sup></italic> control EAE mice (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Since NeuN-staining can be compromised in the chronic phase of EAE, we corroborated our findings by using the neuronal marker HuC/D as an alternative staining of spinal cord neurons (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1G</xref>). Notably, <italic>Ppargc1a</italic> deletion in neurons did not result in different neuronal numbers in healthy mice by using NeuN staining (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1H</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Neuronal <italic>Ppargc1a</italic> levels determine neuronal injury and clinical disability in experimental autoimmune encephalomyelitis (EAE).</title><p>(<bold>A</bold>) Mean clinical scores of <italic>Ppargc1a<sup>flx/flx</sup></italic> (n = 6) and <italic>Ppargc1a<sup>flx/fl</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic> (n = 6) mice undergoing EAE. Curves show mean ± s.e.m. (<bold>B</bold>) Representative images and analysis of immunohistochemical stainings of surviving NeuN-positive neurons in cervical spinal cord ventral horn (VH) or gray matter (GM) of <italic>Ppargc1a</italic><sup>flx/flx</sup> (n = 4) and <italic>Ppargc1a<sup>flx/flx</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic> (n = 4) mice (two areas per mice) at day 40 post-immunization with quantification. Bars show mean values ± s.e.m. Scale bar 100 µm. (<bold>C</bold>) Mean clinical scores of wild-types (n = 31) and Thy1-Ppargc1a (n = 22) mice undergoing EAE. Curves show mean ± s.e.m., all pooled from three independent experiments. (<bold>D</bold>) Histopathological stainings of T cells (CD3), microglia (IBA1), and macrophages (MAC-3) in cervical spinal cord sections of wild-type (n = 6) and Thy1-Ppargc1a (n = 5) mice (2–3 stainings per mice) at day 15 post immunization with quantifications. Bars show mean values ± s.e.m. Scale bar 250 and 100 µm. (<bold>E</bold>) Quantification of cytochrome <italic>c</italic> oxidase (COX) histochemistry of cervical spinal cord GM or VH of wild-type (n = 6) and Thy1-Ppargc1a (n = 4) mice (2–3 stainings per mice) at acute stage of EAE normalized to neuronal nuclei (NeuN)-positive neurons. Bars show mean values ± s.e.m. Scale bar 250 µm. (<bold>F</bold>) Representative images and analysis of immunohistochemical stainings of surviving NeuN-positive neurons in cervical spinal cord VH or GM and surviving neurofilament-positive axons in the dorsal columns of wild-type (n = 5) and Thy1-Ppargc1a (n = 5) (two areas per mice for NeuN, three areas per mice for neurofilament) at day 40 post immunization. Bars show mean values ± s.e.m. Scale bar: 100 µm and 50 µm. Statistical analysis in <bold>A</bold> and <bold>C</bold> was performed by one-tailed Mann–Whitney U test of area under the curve (AUC) starting at peak (day 15) of disease; in <bold>B</bold>, <bold>D</bold>, <bold>E</bold>, and <bold>F</bold> by unpaired, two-tailed Student’s t-test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Numerical data of clinical scores of <italic>Ppargc1a<sup>flx/flx</sup></italic> (flx/flx) (<italic>n</italic> = 6) and <italic>Ppargc1a<sup>flx/flx</sup> × Eno2<sup>Cre+</sup></italic> (flx/flx × Eno2Cre) (n = 6) mice undergoing experimental autoimmune encephalomyelitis (EAE).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-61798-fig5-data1-v3.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Numerical data of clinical scores of wild-types (WT) (<italic>n</italic> = 31) and Thy1-Ppargc1a (TT) (n = 22) mice undergoing experimental autoimmune encephalomyelitis (EAE).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-61798-fig5-data2-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61798-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Neuronal <italic>Ppargc1a</italic> and <italic>Ppargc1a</italic>-dependent target genes are decreased in <italic>Ppargc1a<sup>flx/flx</sup> </italic>× <italic>Eno2<sup>Cre+ </sup></italic>mice.</title><p>(<bold>A</bold>) Relative qPCR mRNA expression of <italic>Eno2</italic> to <italic>Tbp</italic> in hippocampal primary neuronal cultures (hPNC) (DIV14) of wild-type (n = 3) mice. Bars show mean values ± s.e.m. (<bold>B</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> in sorted immune cells in relation to hPNC (DIV14) of wild-type (n = 3) mice. Bars show mean values ± s.e.m. (<bold>C</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> in hippocampus (Hip), cortex, and cervical spinal cord (SC) of <italic>Ppargc1a<sup>flx/flx</sup></italic> (n = 3) and <italic>Ppargc1a<sup>flx/flx</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic> (n = 3) mice. Bars show mean values ± s.e.m. (<bold>D</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> target genes in hippocampus of <italic>Ppargc1a<sup>flx/flx</sup></italic> (n = 3) and <italic>Ppargc1a<sup>flx/flx</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic> (n = 3) mice. Bars show mean values ± s.e.m. (<bold>E</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> target genes in cortex of <italic>Ppargc1a<sup>flx/flx</sup></italic> (n = 3) and <italic>Ppargc1a<sup>flx/flx</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic> (n = 3) mice. Bars show mean values ± s.e.m. (<bold>F</bold>) Relative qPCR mRNA expression of <italic>Ppargc1a</italic> target genes in cervical spinal cord of <italic>Ppargc1a<sup>flx/flx</sup></italic> (n = 3) and <italic>Ppargc1a<sup>flx/flx</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic> (n = 3) mice. Bars show mean values ± s.e.m. (<bold>G</bold>) Analysis of immunohistochemical stainings and quantification of HuC/HuD-positive neurons in cervical spinal cord ventral horn (VH) or gray matter (GM) of <italic>Ppargc1a<sup>flx/flx</sup></italic> (n = 4) and <italic>Ppargc1a<sup>flx/flx</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic> (n = 4) mice (two areas per mouse) at day 40 post-immunization. Bars show mean values ± s.e.m. (<bold>H</bold>) Analysis of immunohistochemical stainings and quantification of neuronal nuclei (NeuN)-positive neurons in cervical spinal cord VH or GM of healthy <italic>Ppargc1a<sup>flx/flx</sup></italic> (n = 5) and <italic>Ppargc1a<sup>flx/flx</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic> (n = 5) mice (two areas per mouse). Bars show mean values ± s.e.m. (<bold>I</bold>) Analysis of immunohistochemical stainings and quantification of surviving HuC/HuD-positive neurons in cervical spinal cord VH or GM of wild-type (n = 5) and Thy1-Ppargc1a (n = 6) (two areas per mice for NeuN, three areas per mice for neurofilament) at day 40 post immunization. Bars show mean values ± s.e.m. (<bold>J</bold>) Analysis of immunohistochemical stainings and quantification of NeuN-positive neurons in cervical spinal cord VH or GM of healthy wild-type (n = 5) and Thy1-Ppargc1a (n = 5) (two areas per mice) immunization. Bars show mean values ± s.e.m. Statistical analysis in <bold>B</bold> was performed by multiple comparisons test following one-way ANOVA, and in <bold>C–J</bold> by unpaired, two-tailed Student’s t-test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61798-fig5-figsupp1-v3.tif"/></fig></fig-group><p>As we observed that neuronal <italic>Ppargc1a</italic> overexpression led to an increased oxidative phosphorylation and improved calcium buffering capacities, we next tested its translatability to the preclinical MS model. EAE induction in Thy1-Ppargc1a and wild-type littermate control mice resulted in a comparable maximum score in the acute phase of the disease. However, Thy1-Ppargc1a mice showed a significantly better recovery from clinical disability in comparison to wild-type controls (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>). Notably, this protection is unlikely to be driven by an impaired immune response as numbers of infiltrating CD3<sup>+</sup> T cells, activated IBA1<sup>+</sup> microglia, and MAC-3<sup>+</sup> macrophages were similar to WT mice (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Moreover, neuronal overexpression of <italic>Ppargc1a</italic> resulted in a rescue of complex IV activity during acute EAE in the entire gray matter and ventral horn (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), leading to a significant reduction of neuronal loss in the gray matter and ventral horn and more intact axons at day 40 post immunization by using NeuN or HuC/HuD as neuronal marker (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1I</xref>). Neuronal <italic>Ppargc1a</italic> overexpression did also not influence neuronal numbers in healthy mice by using NeuN staining (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1J</xref>).</p><p>Thus, induction of neuronal mitochondrial activity represents an attractive neuroprotective strategy in CNS inflammation by compensating mitochondrial dysfunction.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we show that neuronal oxidative phosphorylation is compromised during CNS inflammation, which directly contributes to neuronal vulnerability and can be counteracted by induction of neuronal mitochondrial activity.</p><p>In an unsupervised survey, we discovered that expression of mitochondrial genes is massively suppressed in motor neurons during CNS inflammation (<xref ref-type="bibr" rid="bib57">Schattling et al., 2019</xref>) and here in particular genes that participate in oxidative phosphorylation. This sparked our interest to explore upstream mechanisms that coordinate this mitochondrial shutdown and whether counter-regulation could rescue neuronal integrity. Our observation is in concordance with other reports that showed alterations of mitochondria in the brain of MS patients with compromised oxidative phosphorylation in demyelinated axons and neurons (<xref ref-type="bibr" rid="bib5">Campbell et al., 2011</xref>; <xref ref-type="bibr" rid="bib36">Mahad et al., 2009</xref>). This could potentially contribute to mitochondrial swelling and dysfunction of axons in EAE (<xref ref-type="bibr" rid="bib43">Nikić et al., 2011</xref>; <xref ref-type="bibr" rid="bib55">Sadeghian et al., 2016</xref>). While we could not detect a decrease in somatic neuronal mitochondrial numbers in the spinal cord during EAE, we discovered a compromised complex IV activity in the spinal cord gray matter. This compromised oxidative phosphorylation during CNS inflammation is likely coordinated by inactivation of PGC-1α, a transcriptional coactivator that acts as a master switch of mitochondrial function (<xref ref-type="bibr" rid="bib39">Mootha et al., 2003</xref>; <xref ref-type="bibr" rid="bib50">Puigserver et al., 1998</xref>). However, in contrast to MS patients, in which a marked decrease in cortical PGC-1α expression has been reported (<xref ref-type="bibr" rid="bib64">Witte et al., 2013</xref>), we could not detect a regulation of <italic>Ppargc1a</italic> in inflamed mouse motor neurons.</p><p>By contrast, our data show that CNS inflammation results in a post-translational modification of PGC-1α (<xref ref-type="bibr" rid="bib13">Fernandez-Marcos and Auwerx, 2011</xref>). Increased phosphorylation of serine 570 leads to an inactivation of PGC-1α, which could be mediated by increased AKT activity (<xref ref-type="bibr" rid="bib31">Li et al., 2007</xref>). Three different isoforms of AKT exist. Whereas AKT1 and AKT3 are mainly expressed in neurons, AKT2 is predominantly expressed in astrocytes (<xref ref-type="bibr" rid="bib30">Levenga et al., 2017</xref>). So far, the exact function of AKT in neurons is not clear, but AKT1 has been implicated in late long-term potentiation (<xref ref-type="bibr" rid="bib30">Levenga et al., 2017</xref>) and AKT3 in neuronal growth (<xref ref-type="bibr" rid="bib1">Adams et al., 2016</xref>; <xref ref-type="bibr" rid="bib51">Rivière et al., 2012</xref>). AKT is activated by phosphatidylinositol 3-kinase (PI3K), and the PI3K/AKT signaling pathway is known to reduce apoptosis and promote survival and proliferation (<xref ref-type="bibr" rid="bib2">Brunet et al., 1999</xref>) and thereby counteracts neuronal cell death (<xref ref-type="bibr" rid="bib49">Peltier et al., 2007</xref>). As TNF-α activates the PI3K/AKT pathway (<xref ref-type="bibr" rid="bib21">Gu et al., 2006</xref>; <xref ref-type="bibr" rid="bib32">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib46">Osawa et al., 2001</xref>), upregulation of AKT could function as an immediate strategy of neurons against cell death during inflammation. As a trade-off, prolonged downregulation of mitochondrial gene transcripts will reduce ATP levels that could limit neuronal integrity during chronic inflammation. Thus, tuning <italic>Ppargc1a</italic> could act as a switch that modulates oxidative phosphorylation by regulating respective mitochondrial genes under challenging environmental conditions, such as CNS inflammation.</p><p>This seems to be particularly relevant in tissues with a high energy demand, for example, muscle, liver, and CNS in which <italic>Ppargc1a</italic> is highly expressed. While astrocytes are mostly relying on glycolysis, neurons mainly generate their energy by oxidative phosphorylation with low glycolytic capacities (<xref ref-type="bibr" rid="bib4">Camandola and Mattson, 2017</xref>). Therefore, mitochondrial damage and inactivation is particularly deleterious for neuronal metabolism. That <italic>Ppargc1a</italic> is important for neuronal health is supported by our observation of an aggravated EAE disease course in neuron-specific <italic>Ppargc1a</italic>-deficient mice. This is in accordance with the global <italic>Ppargc1a</italic> knockout mice that showed neurological symptoms such as myoclonus, dystonia, and limb clasping that was attributed to axonal striatal degeneration (<xref ref-type="bibr" rid="bib33">Lin et al., 2004</xref>), although we were not able to detect this phenotype in our neuron-specific <italic>Ppargc1a</italic> knockout mice.</p><p>While a recent report using <italic>Ppargc1a</italic> overexpression under the <italic>Eno2</italic> promoter led to an ameliorated EAE disease course (<xref ref-type="bibr" rid="bib8">Dang et al., 2019</xref>), we believe that this is mainly driven by suppressing the immune response and not by a neuron-intrinsic effect. As <italic>Eno2</italic> is also expressed in immune cells and especially T cell function is influenced by altered mitochondrial activity (<xref ref-type="bibr" rid="bib3">Buck et al., 2016</xref>), in accordance with our notion, the authors reported a reduced immune cell infiltration, less demyelination, a later EAE onset, and an ameliorated EAE disease course (<xref ref-type="bibr" rid="bib8">Dang et al., 2019</xref>), which are typical features for an immunosuppressive phenotype. By contrast, our data show that specific neuronal overexpression of <italic>Ppargc1a</italic> elevated mitochondrial biogenesis and an improved activity of neuronal oxidative phosphorylation, particularly complex IV, which also resulted in a higher overall mitochondrial membrane potential. Notably, these alterations equipped mitochondria with an improved calcium buffering capacity. Besides MS, rise in neuronal intracellular calcium is one of the hallmarks of neurodegenerative diseases (<xref ref-type="bibr" rid="bib37">Mattson, 2007</xref>). Several mechanisms are relevant that lead to intracellular neuronal Ca<sup>2+</sup> accumulation in EAE (<xref ref-type="bibr" rid="bib59">Siffrin et al., 2015</xref>), among them upregulation of voltage-gated sodium channels, Na<sup>+</sup>-Ca<sup>2+</sup> antiporters (<xref ref-type="bibr" rid="bib7">Craner et al., 2004</xref>), Ca<sup>2+</sup> permeable ion channels (<xref ref-type="bibr" rid="bib18">Friese et al., 2007</xref>; <xref ref-type="bibr" rid="bib56">Schattling et al., 2012</xref>), and nanoscale ruptures of the axonal plasma membrane (<xref ref-type="bibr" rid="bib65">Witte et al., 2019</xref>). Therefore, the improved calcium buffering capacity in Thy1-Ppargc1a neurons could efficiently rescue calcium overload and neuronal demise, which was indicated by an increased neuronal survival during EAE. Calcium uptake by mitochondria holds the promise as a therapeutic strategy for several neurodegenerative diseases (<xref ref-type="bibr" rid="bib29">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Parone et al., 2013</xref>). As neuronal mitochondrial deficiency is also associated with other neurodegenerative diseases, for example, Alzheimer’s disease (<xref ref-type="bibr" rid="bib47">Pannaccione et al., 2020</xref>), induction of mitochondrial activity could serve as a unifying neuroprotective approach (<xref ref-type="bibr" rid="bib42">Murphy and Hartley, 2018</xref>). Similarly, downstream targets of <italic>Ppargc1a</italic> are repressed in dopaminergic neurons of Parkinson's disease patients (<xref ref-type="bibr" rid="bib70">Zheng et al., 2010</xref>) in which neuronal overexpression of <italic>Ppargc1a</italic> protects dopaminergic neurons in its mouse model (<xref ref-type="bibr" rid="bib41">Mudò et al., 2012</xref>).</p><p>As we detected a higher neuronal resilience in Thy1-Ppargc1a mice during CNS inflammation, pharmacological increase of neuronal mitochondria and oxidative phosphorylation could be a promising neuroprotective strategy. Some drugs have already been described to induce <italic>Ppargc1a</italic> in different tissues (<xref ref-type="bibr" rid="bib10">Dumont et al., 2012</xref>; <xref ref-type="bibr" rid="bib24">Hofer et al., 2014</xref>; <xref ref-type="bibr" rid="bib45">Noe et al., 2013</xref>; <xref ref-type="bibr" rid="bib68">Ye et al., 2012</xref>); however, we could not confirm neuronal induction of <italic>Ppargc1a</italic> by treating mice with bezafibrate or using transient receptor potential cation channel subfamily V member 4 (<italic>Trpv4</italic>) knockout mice (data not shown). Another possible drug candidate is sirtuin-1 that activates PGC-1α by deacetylation, and its neuronal overexpression leads to an ameliorated EAE disease course (<xref ref-type="bibr" rid="bib44">Nimmagadda et al., 2013</xref>). Besides extrinsic induction or activation of <italic>Ppargc1a</italic>, it can also be induced by intrinsic mechanisms such as cold exposure or exercise (<xref ref-type="bibr" rid="bib34">Lin et al., 2005</xref>). Exercise ameliorates the EAE disease course (<xref ref-type="bibr" rid="bib28">Klaren et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Rossi et al., 2009</xref>) and shows several benefits in MS patients (<xref ref-type="bibr" rid="bib40">Motl et al., 2017</xref>); however, the proof of a neuroprotective effect that is mediated by <italic>Ppargc1a</italic> induction is currently outstanding.</p><p>Taken together, we provide evidence for a therapeutic potential of inducing mitochondrial activity in inflammation-induced neurodegeneration, supporting further studies that aim at finding drugs to target this pathway in neurons.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Antibody</td><td>Alexa Fluor 488 <break/>α-chicken <break/>(donkey polyclonal)</td><td>Jackson</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2340375">AB_2340375</ext-link></td><td>IHC (1:800)</td></tr><tr><td>Antibody</td><td>Alexa Fluor 647 <break/>α-rabbit <break/>(donkey polyclonal)</td><td>Jackson</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2752244">AB_2752244</ext-link></td><td>IHC (1:800)</td></tr><tr><td>Antibody</td><td>α-NeuN <break/>(chicken polyclonal)</td><td>Millipore</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11205760">AB_11205760</ext-link></td><td>IHC (1:500)</td></tr><tr><td>Antibody</td><td>α-HuC/HuD <break/>(mouse monoclonal)</td><td>Thermo Scientific</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_221448">AB_221448</ext-link></td><td>IHC (1:500)</td></tr><tr><td>Antibody</td><td>α-Mouse IgG <break/>(goat polyclonal)</td><td>Jackson</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2338476">AB_2338476</ext-link></td><td>IHC (1:200)</td></tr><tr><td>Antibody</td><td>Cy3 α-mouse <break/>(donkey polyclonal)</td><td>Jackson</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2340816">AB_2340816</ext-link></td><td>IHC (1:800)</td></tr><tr><td>Antibody</td><td>α-FLAG (Clone M2) <break/>(mouse monoclonal)</td><td>Sigma</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_259529">AB_259529</ext-link></td><td>IHC (1:200)</td></tr><tr><td>Antibody</td><td>α-SMI31 <break/>(mouse monoclonal)</td><td>Covance</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10122491">AB_10122491</ext-link></td><td>IHC (1:500)</td></tr><tr><td>Antibody</td><td>α-SMI32 <break/>(mouse monoclonal)</td><td>Covance</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2564642">AB_2564642</ext-link></td><td>IHC (1:500)</td></tr><tr><td>Antibody</td><td>α-PGC-1α <break/>(rabbit polyclonal)</td><td>Novus</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1522118">AB_1522118</ext-link></td><td>IHC (1:100) <break/>ICC (1:200) <break/>WB (1:2000)</td></tr><tr><td>Antibody</td><td>α-MAP2 <break/>(chicken polyclonal)</td><td>Abcam</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2138153">AB_2138153</ext-link></td><td>ICC (1:2500)</td></tr><tr><td>Antibody</td><td>α-CD3 (clone SP7) <break/>(rabbit monoclonal)</td><td>Abcam</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_443425">AB_443425</ext-link></td><td>IHC (1:100)</td></tr><tr><td>Antibody</td><td>α-Mac3 (clone M3/84) <break/>(rat monoclonal)</td><td>BD Biosciences</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_394780">AB_394780</ext-link></td><td>IHC (1:100)</td></tr><tr><td>Antibody</td><td>α-Iba1 <break/>(rabbit polyclonal)</td><td>Wako</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_839504">AB_839504</ext-link></td><td>IHC (1:100)</td></tr><tr><td>Antibody</td><td>α-Phosphorylated PGC-1αS570 <break/>(rabbit polyclonal)</td><td>R and D Systems</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10890391">AB_10890391</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>α-ß-Actin <break/>(rabbit polyclonal)</td><td>Cell Signaling Technology</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330288">AB_330288</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>HRP α-rabbit <break/>(goat polyclonal)</td><td>LI-COR Biosciences</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2721264">AB_2721264</ext-link></td><td>WB (1:15,000)</td></tr><tr><td>Antibody</td><td>α-CD45-APC/Cy7 (clone 30F11) <break/>(rat monoclonal)</td><td>BioLegend</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312981">AB_312981</ext-link></td><td>FACS (1:100)</td></tr><tr><td>Antibody</td><td>α-CD4-FITC (clone GK1.5) <break/>(rat monoclonal)</td><td>BioLegend</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312691">AB_312691</ext-link></td><td>FACS (1:100)</td></tr><tr><td>Antibody</td><td>α-CD3-BV605 (clone 17A2) <break/>(rat monoclonal)</td><td>BioLegend</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2562039">AB_2562039</ext-link></td><td>FACS (1:300)</td></tr><tr><td>Antibody</td><td>α-CD8-Pacific Blue (clone 53–6.7) <break/>(rat monoclonal)</td><td>BioLegend</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493425">AB_493425</ext-link></td><td>FACS (1:100)</td></tr><tr><td>Antibody</td><td>α-CD19-PE/Cy7 (clone 1D3) <break/>(rat monoclonal)</td><td>BD</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10894021">AB_10894021</ext-link></td><td>FACS (1:100)</td></tr><tr><td>Antibody</td><td>α-CD19-BV605 (clone 6D5) <break/>(rat monoclonal)</td><td>BioLegend</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11203538">AB_11203538</ext-link></td><td>FACS (1:100)</td></tr><tr><td>Antibody</td><td>α-Ly6G-BV711 (clone 1A8) <break/>(rat monoclonal)</td><td>BD</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2738520">AB_2738520</ext-link></td><td>FACS (1:100)</td></tr><tr><td>Antibody</td><td>α-F4/80-BV421 (clone T45-2342) <break/>(rat monoclonal)</td><td>BD</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2734779">AB_2734779</ext-link></td><td>FACS (1:100)</td></tr><tr><td>Antibody</td><td>α-NK1.1- PE/Cy7 (clone PK136) <break/>(rat monoclonal)</td><td>BioLegend</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_389364">AB_389364</ext-link></td><td>FACS (1:300)</td></tr><tr><td>Antibody</td><td>α-CD11b-FITC (clone M1/70) <break/>(rat monoclonal)</td><td>BioLegend</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312789">AB_312789</ext-link></td><td>FACS (1:300)</td></tr><tr><td>Antibody</td><td>α-Fc-Block (true stain anti-mouse CD16/32, clone 93) <break/>(rat monoclonal)</td><td>BioLegend</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1574975">AB_1574975</ext-link></td><td>FACS (1:1000)</td></tr><tr><td>Chemical compound, drug</td><td><italic>Mycobacterium tuberculosis</italic></td><td>BD Difco</td><td>BD 231141</td><td/></tr><tr><td>Chemical compound, drug</td><td>Freund’s adjuvant</td><td>Difco Laboratories</td><td>Cat. number: 263910</td><td/></tr><tr><td>Chemical compound, drug</td><td>Dynabeads MyOne Streptavidin T1</td><td>Invitrogen</td><td>Cat. number: <break/>65601</td><td/></tr><tr><td>Chemical compound, drug</td><td>Cytochrome <italic>c</italic> from bovine heart</td><td>Sigma-Aldrich</td><td>CAS number:9007-43-6</td><td/></tr><tr><td>Chemical compound, drug</td><td>Bis(2-amino-phenoxy) ethane tetraacetic acid</td><td>Thermo Scientific</td><td>CAS number: 126150-97-8</td><td/></tr><tr><td>Chemical compound, drug</td><td>3,3-Diaminobenzidine (DAB),≥98%</td><td>Sigma-Aldrich</td><td>Cat. number: D8001</td><td/></tr><tr><td>Chemical compound, drug</td><td>Fluo-4, AM</td><td>Invitrogen</td><td>Cat. number: F14201</td><td/></tr><tr><td>Commercial assay or kit</td><td>Bicinchoninic acid (BCA) kit for protein determination</td><td>Sigma-Aldrich</td><td>Cat. number: <break/>BCA1</td><td/></tr><tr><td>Commercial assay or kit</td><td>Seahorse XF cell mito stress test kit</td><td>Agilent</td><td>Part number: 103015-100</td><td/></tr><tr><td>Commercial assay or kit</td><td>Calcein-AM</td><td>Sigma-Aldrich</td><td>CAS number: 14850434–1</td><td/></tr><tr><td>Commercial assay or kit</td><td>ultraView Universal DAB detection kit</td><td>Ventana</td><td>Cat. number: <break/>760-500</td><td/></tr><tr><td>Commercial assay or kit</td><td>TMRE-mitochondrial membrane potential assay kit</td><td>Abcam</td><td>Ab113852</td><td/></tr><tr><td>Genetic reagent (<italic>Mus musculus</italic>)</td><td>C57BL/6J wild-type mice</td><td>Jackson Laboratory</td><td>Stock #: 000664 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:MGI:2159769">MGI:2159769</ext-link></td><td/></tr><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td>Thy1-Flag-Ppargc1a</td><td>PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/21984601">21984601</ext-link></td><td/><td>Dr. Dan Lindholm (Minerva Medical Research Institute)</td></tr><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td><italic>Eno2<sup>Cre+</sup></italic></td><td>Jackson Laboratory</td><td>Stock #: 006663 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:2177175">MGI:2177175</ext-link></td><td/></tr><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td><italic>Ppargc1a<sup>flx/flx</sup></italic></td><td>Jackson Laboratory</td><td>Stock #: 009666 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:MGI:5576884">MGI:5576884</ext-link></td><td/></tr><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td><italic>Chat-L10a-eGFP</italic></td><td>Jackson Laboratory</td><td>Stock #: 030250 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:5496680">MGI:5496680</ext-link></td><td/></tr><tr><td>Other</td><td>Bolt 4–12% Bis-Tris Plus Gel</td><td>Invitrogen</td><td>Cat. number: NW04120BOX</td><td/></tr><tr><td>Peptide, recombinant protein</td><td>MOG<sub>35-55</sub> peptide</td><td>Peptides and elephants</td><td>Order number: EP02030_1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Actb</italic></td><td>Thermo Scientific</td><td>Mm_00607939_s1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Alas</italic></td><td>Thermo Scientific</td><td>Mm01235914_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Coq9</italic></td><td>Thermo Scientific</td><td>Mm00804236_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Cox2I</italic></td><td>Thermo Scientific</td><td>Mm03294838_g1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Cox4iI</italic></td><td>Thermo Scientific</td><td>Mm01250094_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Cox5a</italic></td><td>Thermo Scientific</td><td>Mm00432638_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Cox5b</italic></td><td>Thermo Scientific</td><td>Mm01229713_g1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Cox6a1</italic></td><td>Thermo Scientific</td><td>Mm01612194_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Cs</italic></td><td>Thermo Scientific</td><td>Mm00466043_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Cyc1</italic></td><td>Thermo Scientific</td><td>Mm00470540_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Iscu</italic></td><td>Thermo Scientific</td><td>Mm02342800_g1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Ndufa10</italic></td><td>Thermo Scientific</td><td>Mm00600325_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Ndufa12</italic></td><td>Thermo Scientific</td><td>Mm01240336_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Ndufa8</italic></td><td>Thermo Scientific</td><td>Mm00503351_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Ndufb6</italic></td><td>Thermo Scientific</td><td>Mm07294890_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Ndufs8</italic></td><td>Thermo Scientific</td><td>Mm00523063_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Nrf1</italic></td><td>Thermo Scientific</td><td>Mm01135606_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Ppargc1a</italic></td><td>Thermo Scientific</td><td>Mm00464452_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Sdha</italic></td><td>Thermo Scientific</td><td>Mm01352366_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Sdhb</italic></td><td>Thermo Scientific</td><td>Mm00458272_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Sdhd</italic></td><td>Thermo Scientific</td><td>Mm00546511_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Slc25a12</italic></td><td>Thermo Scientific</td><td>Mm00552467_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Sod2</italic></td><td>Thermo Scientific</td><td>Mm01313000_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Tbp</italic></td><td>Thermo Scientific</td><td>Mm01277042_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Tfam</italic></td><td>Thermo Scientific</td><td>Mm00447485_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Uqcr10</italic></td><td>Thermo Scientific</td><td>Mm01186961_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Uqcrb</italic></td><td>Thermo Scientific</td><td>Mm01615741_gH</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Ppargc1a</italic></td><td>Thermo Scientific</td><td>Mm00164544_cn, FAM</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Tfrc</italic></td><td>Thermo Scientific</td><td>TaqMan Copy Number reference Assay for mouse, VIC</td><td/></tr><tr><td>Transfected construct (synthetic)</td><td>pAAV.Syn.GCaMP6f.WPRE.SV40</td><td>Abcam</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_100837">Addgene_100837</ext-link></td><td>Cytosolic calcium indicator</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>All mice (C57BL/6J wild type [The Jackson Laboratory, Bar Harbor, USA], Thy1-Flag-Ppargc1a [Thy1-Ppargc1a] mice on a C57BL/6J genetic background provided by D. Lindholm [<xref ref-type="bibr" rid="bib41">Mudò et al., 2012</xref>], <italic>Eno2<sup>Cre+</sup></italic> mice [The Jackson Laboratory], <italic>Ppargc1a<sup>flx/flx</sup></italic> mice [The Jackson Laboratory], and <italic>Chat</italic>-L10a-eGFP mice [<xref ref-type="bibr" rid="bib22">Heiman et al., 2008</xref>]) were kept under specific pathogen-free conditions in the central animal facility of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Neuron-specific knockout mice were generated by crossing <italic>Ppargc1a<sup>flx/flx</sup></italic> with <italic>Eno2<sup>Cre+</sup></italic> mice. Mice were grouped housed in a facility with 55–65% humidity at 24 ± 2°C with a 12 hr light/dark cycle and had free access to food and water. Sex- and age-matched adult animals (10–20 weeks of age) were used in all experiments. Wild-type mice were allocated to EAE or healthy group by cages. All procedures were carried out in accordance with the ARRIVE guidelines (<xref ref-type="bibr" rid="bib27">Kilkenny et al., 2010</xref>).</p></sec><sec id="s4-2"><title>EAE induction</title><p>Mice were anesthetized with isoflurane 1–2% v/v oxygen and immunized subcutaneously with 200 μg myelin oligodendrocyte glycoprotein 35–55 (MOG<sub>35–55</sub>) peptide (peptides and elephants) in complete Freund’s adjuvant (BD) containing 4 mg/ml <italic>Mycobacterium tuberculosis</italic> (BD, Franklin Lakes, USA). A 200 ng pertussis toxin (Merck, Darmstadt, Germany) was injected intravenously on the day of immunization and 48 hr later. Animals were scored daily for clinical signs by the following system: 0, no clinical deficits; 1, tail weakness; 2, hind limb paresis; 3, partial hind limb paralysis; 3.5, full hind limb paralysis; 4, full hind limb paralysis and forelimb paresis; and 5, premorbid or dead. Animals reaching a clinical score ≥4 were sacrificed according to the regulations of the Animal Welfare Act. The experimenters were blinded to the genotype until the end of the experiment, including data analysis. Sex- and age-matched adult animals (8–12 weeks of age) were used in all experiments. For Thy1-Ppargc1a mice and wild-type controls, three independent EAE experiments were conducted, and the data were pooled for final analysis. For <italic>Ppargc1a<sup>flx/flx</sup></italic> × <italic>Eno2<sup>Cre+</sup></italic> EAE and <italic>Ppargc1a<sup>flx/flx</sup></italic> controls, one EAE was conducted. For analysis of the disease course and weight, we only included animals that received a score ≥1 until day 15 and survived until the end of the experiment. Animals were either analyzed at acute stage of EAE (day 12 to day 16 after immunization) or chronic stage (day 30 to day 40 after immunization).</p></sec><sec id="s4-3"><title>Gene set enrichment analysis</title><p>Gene signature of motor neurons during CNS inflammation was generated by ranking all expressed genes by the DESeq2-derived t statistics based on the comparison of healthy versus EAE motor neurons (<xref ref-type="bibr" rid="bib57">Schattling et al., 2019</xref>). Enrichment analysis was performed using the function ‘gseGO’ of the R package clusterProfiler (<xref ref-type="bibr" rid="bib69">Yu et al., 2012</xref>) on biological process GO terms with at least 50 members. Gene sets with a Benjamini–Hochberg adjusted p value &lt;0.05 were considered significant and ordered by their normalized enrichment score, with positive values indicating enrichment and negative values indicating de-enrichment. Core enrichment genes driving the de-enrichment of the term ‘GO:0022900 electron transport chain’ were extracted from clusterProfiler results and plotted as heatmap of gene expression values after variance stabilizing transformation. Plotting was performed with the R packages ggplot2 (<ext-link ext-link-type="uri" xlink:href="https://ggplot2.tidyverse.org">https://ggplot2.tidyverse.org</ext-link>; <xref ref-type="bibr" rid="bib63">Wickham, 2016</xref>), clusterProfiler and tidyheatmaps (<xref ref-type="bibr" rid="bib11">Engler, 2020</xref>).</p></sec><sec id="s4-4"><title><italic>Ppargc1a</italic> target identification</title><p>For the identification of <italic>Ppargc1a-</italic>induced downstream targets, a published microarray dataset of <italic>Ppargc1a</italic>-overexpressing SH-SY5Y cells was used (<xref ref-type="bibr" rid="bib35">Lucas et al., 2014</xref>). The expression matrix was downloaded via GEOquery (GSE100341) and analyzed using limma. Genes with a false discovery rate (FDR)-adjusted p value &lt;0.05 and a log2 fold change &gt;1 in <italic>Ppargc1a</italic> overexpression were considered positively regulated <italic>Ppargc1a</italic> targets.</p></sec><sec id="s4-5"><title>Mouse tissue preparation and histopathology of mice</title><p>Mice were anesthetized intraperitoneally with 100 µl solution (10 mg/ml esketamine hydrochloride [Pfizer, New York City, USA], 1.6 mg/ml xylazine hydrochloride [Bayer, Leverkusen, Germany] dissolved in water) per 10 g of body weight. For histopathology and immunohistochemistry, mice were perfused with 4% paraformaldehyde (PFA), cervical spinal cord tissue was dissected, fixed for 30 min with 4% PFA, and then transferred to 30% sucrose in phosphate-buffered saline (PBS) at 4°C. Cervical spinal cord was used as it was shown that clinical scores correlate better with cervical than lumbar spinal cord lesions in EAE (<xref ref-type="bibr" rid="bib17">Fournier et al., 2017</xref>). We transversely cut midcervical spinal cord sections at 12 μm with a freezing microtome (Leica Jung CM3000) and stored them in cryoprotective medium (Jung) at –80°C. For transmission electron microscopy, mice were perfused with 4% PFA, 1% glutaraldehyde (GA) in 0.1 M phosphate buffer, and spinal cords were dissected and fixed with 2% PFA, 2.5% GA in 0.1 M phosphate buffer. Antibodies directed against CD3 (rabbit IgG, Abcam, Cambridge, UK; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_443425">AB_443425</ext-link>), Mac-3 (rat IgG, BD Biosciences; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_394780">AB_394780</ext-link>), and Iba1 (rabbit, Wako, Richmond, USA; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_839504">AB_839504</ext-link>) were visualized by avidin-biotin technique with 3,3-diaminobenzidine (DAB, Sigma, St.Louis, USA) according to standard procedures of the UKE Mouse Pathology Facility using the ultraView Universal DAB Detection Kit (Ventana, Oro Valley, USA). For complex IV/cytochrome <italic>c</italic> oxidase (COX) histochemistry, sections were incubated for 60 min at 37°C with COX reaction media (diaminobenzidine tetrahydrochloride, cytochrome <italic>c</italic> and bovine catalase [all from Sigma] in 0.2 M phosphate buffer) and embedded with Aquatex (Merck). Images of tissue sections at ×200 magnification were scanned using Zeiss MIRAX MIDI Slide Scanner (Carl Zeiss, MicroImaging GmbH, Germany). CD3<sup>+</sup>, IBA1<sup>+</sup>, and MAC-3<sup>+</sup> infiltrating cells were analyzed with ImageJ software (NIH, Bethesda, USA), with the same settings across all experimental groups. CD3<sup>+</sup> cells were counted in entire spinal cord sections. For IBA1<sup>+</sup> and MAC3<sup>+</sup> quantification, we calculated the percentage of the positively stained area in the spinal cord. For quantification of complex IV activity, background was subtracted and mean gray value intensities of COX reactivity in complete gray matter or the ventral horn were measured by ImageJ. COX reactivity was normalized to corresponding neuronal count.</p></sec><sec id="s4-6"><title>Immunohistochemistry (IHC)</title><p>Sections were incubated in blocking solution (10% normal donkey serum in PBS) containing 0.05% Triton X-100 at room temperature for 45 min, incubated in 0.05% Triton X-100 containing a Fab Fragment anti-mouse IgG (goat, 1:200; Jackson; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2338476">AB_2338476</ext-link>) for 60 min in case of staining anti-mouse primary antibodies to prevent unspecific binding, and subsequently stained them overnight at 4°C with antibodies against the following structures: phosphorylated neurofilaments (SMI 31, mouse, 1:500; Covance, Princeton, USA; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10122491">AB_10122491</ext-link>), non-phosphorylated neurofilaments (SMI 32, mouse, 1:500; Covance; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2564642">AB_2564642</ext-link>), neuronal nuclei (NeuN, chicken 1:500; Millipore, Burlington, USA; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11205760">AB_11205760</ext-link>), neuronal protein (HuC/D, mouse 1:500; Thermo Fisher Scientific, Waltham, USA; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_221448">AB_221448</ext-link>), PGC-1α (PGC-1α, rabbit, 1:100; Novus Biologicals, Littleton, USA; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1522118">AB_1522118</ext-link>), and FLAG sequence (FLAG, mouse, 1:200; Sigma; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_259529">AB_259529</ext-link>). As secondary antibodies we used Alexa Fluor 488-coupled donkey antibodies recognizing chicken IgG (1:800, Jackson; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2340375">AB_2340375)</ext-link>, Cy3-coupled donkey antibodies recognizing mouse IgG (1:800, Jackson; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2340816">AB_2340816</ext-link>), and Alexa Fluor 647-coupled donkey antibodies recognizing rabbit IgG (1:800, Abcam; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2752244">AB_2752244</ext-link>). We analyzed the sections with a Zeiss LSM 700 confocal microscope. For quantification of neurons and axons, tile scans of each animal were taken. Numbers of neurons were manually counted in two defined areas (250 µm × 250 µm) from the central gray matter or ventral horn. For absolute numbers of neurons in the ventral horn, all neurons in both ventral horns per animals were counted. Axons were quantified in three defined areas (90 µm × 90 µm) with ImageJ software using fixed threshold intensity across experimental groups for each type of tissue examined.</p></sec><sec id="s4-7"><title>Immunocytochemistry (ICC) </title><p>Cortical neurons (DIV14) were fixed with 4% PFA for 30 min at room temperature, permeabilized with 0.05% Triton and blocked with 10% normal donkey serum in PBS. Cells were stained overnight at 4°C with antibodies directed against PGC-1α (PGC-1α, rabbit, 1:200; Novus Biologicals; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1522118">AB_1522118</ext-link>) and microtubule-associated protein 2 (MAP2, chicken, 1:2500; Abcam; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2138153">AB_2138153</ext-link>). As secondary antibodies we used Alexa Fluor 488-coupled donkey antibodies recognizing chicken IgG (1:800, Jackson; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2340375">AB_2340375)</ext-link>, Cy3-coupled donkey antibodies recognizing mouse IgG (1:800, Jackson; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2340816">AB_2340816</ext-link>), and Alexa Fluor 647-coupled donkey antibodies recognizing rabbit IgG (1:800, Abcam; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2752244">AB_2752244</ext-link>). Images were taken with a Zeiss LSM 700 confocal microscope.</p></sec><sec id="s4-8"><title>Transmission electron microscopy</title><p>After dissection and fixation, spinal cords were cut in 1 mm transverse sections and post-fixed in 1% osmium tetroxide (OsO<sub>4</sub>) for 1 hr. Hereafter, samples were dehydrated in serial dilutions of alcohol and embedded with Epon (LX‐112 Resin, Ladd Research, USA). Next, ultrathin (50‐85 nm) sections were collected on 200 mesh copper grids and counterstained with uranyl acetate and lead citrate. Images of individual motor neurons were taken at ×5000 magnification using a JEM 1010 transmission electron microscope (JEM 1010, Jeol USA). From each motor neuron, we quantified the surface area of neuronal cytoplasm and all cytoplasmic mitochondria using ImageJ (NIH), which were used to calculate mitochondrial density per neuron.</p></sec><sec id="s4-9"><title>Primary neuronal culture</title><p>Primary hippocampal and cortical cultures were prepared from E16.5 embryos. Hippocampus and cortex were harvested, cut into smaller pieces, and incubated in 0.05% Trypsin-EDTA (Gibco) for 6 min at 37°C. Trypsination was stopped by DMEM-F12 containing 10% fetal calf serum (FCS). Afterwards, tissue was dissociated in Hank's balanced salt solution (HBSS) and centrifuged for 2 min at 500 × <italic>g</italic>. The pellet was resuspended in primary growth medium (PGM), and cells were plated at 5 × 10<sup>4</sup> per cm<sup>2</sup> (hippocampal neurons) or 7.5 × 10<sup>4</sup> per cm<sup>2</sup> (cortical neurons) on poly-d-lysine-coated cell culture plates. We maintained cells in PNGM (Primary Neuron Growth Medium BulletKit, Lonza) or neurobasal plus medium (supplemented with B27, penicillin, streptomycin and L-glutamine; Gibco) at 37°C, 5% CO<sub>2</sub>, and a relative humidity of 98%. To inhibit glial proliferation, we added cytarabine (Sigma, 5 µM) or floxuridine/uridine (Sigma, 10 µM) at 3–4 days in vitro (DIV) at 5 μM and maintained cultures for 14–21 days in vitro (DIV14 or DIV21).</p></sec><sec id="s4-10"><title>Calcium imaging</title><p>Cortical primary neurons were transduced with genetically encoded cytosolic calcium indicator GCaMP6f (Addgene 100837) via adeno-associated virus (AAV7) at day 7 in vitro. Calcium imaging was performed from cPNC from E16.5 embryos (DIV15). Alternatively, chemical calcium indicator Fluo4-AM (Thermo Fisher, F14201) was used according to the manufacturer’s instructions. Briefly, cultures were incubated in optic buffer (ddH<sub>2</sub>O supplemented with 10 mM glucose, 140 mM NaCl, 1 mM MgCl<sub>2</sub>, 5 mM KCl, 20 mM HEPES, 2 mM CaCl<sub>2</sub>, pH 7.3 adjusted with NaOH) with 4 µM Fluo4-AM for 30 min at room temperature, washed and imaged in optic buffer. Live cell imaging was performed at day 15 in vitro with a Zeiss LSM 700 confocal microscope, 20× magnification (objective) and temporal resolution of 478 ms. Transduced cultures were placed to incubation chamber (33°C, 5% CO<sub>2</sub>) 20 min prior to imaging and then recorded. Ionomycin (8 µM) was added at the end of each experiment for signal normalization and cultures were imaged for another 15 min to allow development of maximum signal intensity. Additional normalization with optic buffer without Ca<sup>2+</sup> and with 50 µM BAPTA-AM (Thermo Fisher) was done for the experiments using Fluo4-AM as calcium indicator to determine absolute calcium concentration (<xref ref-type="bibr" rid="bib67">Yasuda et al., 2004</xref>). The 478 s of spontaneous Ca<sup>2+</sup> transients before application of ionomycin were used for analysis. Time-series images were generated for further analysis. Manual image segmentation and generation of traces of the intensity from the single neuronal soma was performed in ImageJ. Normalization, calcium spikes, base line detection, and analysis of the calcium clearance rate were performed with the custom-made script written on Python 3.6 (<ext-link ext-link-type="uri" xlink:href="https://github.com/scriptcalcium/PGC1alpha">https://github.com/scriptcalcium/PGC1alpha</ext-link>; <xref ref-type="bibr" rid="bib53">Rosenkranz, 2021</xref>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:9be6b665fa6cd2a737362413f9eb929979d71921;origin=https://github.com/scriptcalcium/PGC1alpha;visit=swh:1:snp:e4c8a5fc8a6e6bbb6492e5c9fe440bca33866055;anchor=swh:1:rev:af3c206a43f8b6e9fdbd7707c9b4601287d5968b/">swh:1:rev:af3c206a43f8b6e9fdbd7707c9b4601287d5968b</ext-link>) (<xref ref-type="bibr" rid="bib58">Shaposhnykov, 2020</xref>). Clearance time (T), amplitude (A), mean signal intensity (Mean), and numbers of calcium transients = firing rate (N) were defined as follows:<disp-formula id="equ1"><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mspace width="thinmathspace"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>≥</mml:mo><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>w</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>a</mml:mi><mml:mo>∈</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mi>δ</mml:mi><mml:mo>…</mml:mo><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>δ</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="thinmathspace"/><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>&gt;</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>θ</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:munderover><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>Firing rate (N<sub>i</sub>): N: calcium transient count; F: normalized signal intensity; i and n: indexes for defined frame (n) and cell (i); parameters δ, θ, and γ were set as 3, 7, and 0.25 for all analyzed cultures by manual assessment of effective pick detection &gt;80%<disp-formula id="equ2"><mml:math id="m2"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mrow><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Clearance time (T<sub>i</sub>): clearance time for the ith cells with detected k transients, from maximum to half of the amplitude<disp-formula id="equ3"><mml:math id="m3"><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mrow><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munderover><mml:mrow><mml:mi>F</mml:mi><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Amplitude (A<sub>i</sub>): amplitude for the ith cell with detected k transients; Fp<sub>i</sub> – amplitude of individual transients of ith cell<disp-formula id="equ4"><mml:math id="m4"><mml:mi>M</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>-</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:mfrac><mml:mrow><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mi>F</mml:mi><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Mean<sub>[a,b]</sub>: mean of recorded signal from frame a till frame b, F(j) – signal extracted from jth frame; parameters a and b were determined for each experiment individually for each experiment with a constant analyzed interval; last frame was recorded before ionomycin addition.</p></sec><sec id="s4-11"><title>Live cell metabolic assay</title><p>Hippocampal neurons were seeded in a poly-d-lysine-coated XF 96-well cell culture microplate (Seahorse Bioscience, Copenhagen, Denmark) in triplicate at 5 × 10<sup>5</sup> cells per well in 1 ml neuronal growth medium and then incubated at 37°C in 5% CO<sub>2</sub>. At DIV14, media from neurons was removed, replaced by 180 µl of assay media (Assay Media from Bioscience with 25 mM glucose, 1 mM sodium pyruvate, and 2 mM L-glutamine; pH 7.4), and incubated in a CO<sub>2</sub>-free incubator at 37°C for 1 hr. Compounds (2 µM oligomycin, 1 µM FCCP, 0.5 µM rotenone/antimycin A, all in assay media) were added into the appropriate ports of a hydrated sensor cartridge. For baseline measurement, control ports were left without compound addition. Cell plate and cartridge were then placed into the XFe96 Analyzer and results analyzed by WAVE Software.</p></sec><sec id="s4-12"><title>Cell viability assay (calcein)</title><p>Hippocampal neurons were seeded in a poly-d-lysine-coated XF 96-well cell culture microplate (Seahorse Bioscience, Copenhagen, Denmark) in quadruplicate at 5 × 10<sup>5</sup> cells per well in 1 ml neuronal growth medium and then incubated at 37°C in 5% CO<sub>2</sub>. At DIV14, calcein-AM (Sigma) was added to the cultures (2 µM), incubated at 37°C in 5% CO<sub>2</sub> for 30 min, washed in optic buffer (ddH<sub>2</sub>O supplemented with 10 mM glucose, 140 mM NaCl, 1 mM MgCl<sub>2</sub>, 5 mM KCl, 20 mM HEPES, 2 mM CaCl<sub>2</sub>, pH 7.3 adjusted with NaOH) at room temperature, and fluorescence intensity was measured according to the manufacturer’s instructions.</p></sec><sec id="s4-13"><title>Mitochondrial membrane potential assay</title><p>Primary neurons were seeded on µ-dishes (ibidi) and TMRE assay (Abcam) was performed on DIV14 according to the manufacturer’s protocol. Cells were treated with 10 nM TMRE for 20 min in PGM, washed twice with HBSS w/o phenol red (Gibco), and then equilibrated for 10 min in HBSS w/o phenol red and live imaged at 555 nm with a Zeiss LSM 700 confocal microscope. For internal control, 20 µM FCCP was added 10 min prior to TMRE. Images were taken with a Zeiss LSM 700 confocal microscope. Total fluorescence of five cells per biological replicate was analyzed.</p></sec><sec id="s4-14"><title>Translating ribosome affinity purification</title><p>Chat-L10a-eGFP mice were anesthetized with ketamin/xylazin and perfused with 10 ml ice-cold dissection buffer (1 × HBSS, 2.5 mM HEPES-KOH pH 7.4, 35 mM glucose, 4 mM NaHCO<sub>3</sub>) over 1 min. Cervical spinal cords were dissected in ice-cold dissection buffer containing 100 µg/ml cycloheximide, and three spinal cords were pooled for homogenization in lysis buffer (20 mM HEPES-KOH pH 7.4, 150 mM KCl, 5 mM MgCl<sub>2</sub>, 0.5 mM dithiothreitol, 100 µg/ml cycloheximide, 40 U/ml Rnasin, 20 U/ml Superasin) using a glass homogenizer. Homogenates were centrifuged at 2000 × <italic>g</italic> for 10 min at 4°C to remove large cell debris, supernatant was transferred to a new tube, and NP-40 detergent solution (Thermo Fisher Scientific) and 1,2-diheptanoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids) were added to final concentrations of 1% and 30 mM, respectively. After 5 min incubation on ice, lysates were centrifuged at 20,000 × <italic>g</italic> for 10 min at 4°C. Ten percent of the supernatant was saved as input control, the remaining 90% were incubated with monoclonal GFP antibody (Htz-GFP19C8 and Htz-GFP19F7; Memorial Sloan Kettering Cancer Center Monoclonal Antibody Core Facility)-coated magnetic beads (Streptavidin MyOne T1 Dynabeads, Invitrogen pre-coupled to biotinylated Protein L, Pierce) with end-over-end rotation overnight at 4°C. Beads were subsequently collected on a magnetic rack, washed four times with high-salt wash buffer (20 mM HEPES, 350 mM KCl, 5 mM MgCl<sub>2</sub>, 0.5 mM, 1% NP-40, 0.5 mM dithiothreitol, 100 μg/ml cycloheximide), and immediately subjected to Trizol/chloroform-based RNA extraction (Invitrogen). RNA was precipitated with sodium acetate and Glycoblue (Ambion, Thermo Fisher Scientific) in isopropanol overnight at –80°C, washed twice with 70% ethanol, resuspended in water, and further purified using the RNeasy Micro Kit (Qiagen, Venlo, The Netherlands) with on-column DNaseI digestion. For higher RNA yields, all steps were carried out in non-stick microfuge tubes (Ambion).</p></sec><sec id="s4-15"><title>Fluorescence-activated cell sorting (FACS)</title><p>Mice were anesthetized and killed by inhalation of CO<sub>2</sub>, and spleens were excised with sterile instruments and collected in ice-cold PBS. Pooled single-cell suspensions from spleen were prepared by homogenization through a 40 μm cell strainer. Cells were pelleted by centrifugation (300 × <italic>g</italic>, 10 min, 4°C), and lysis of splenic erythrocytes was initiated by RBC lysis buffer (0.15 M NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, 0.1 mM Na<sub>2</sub>EDTA, pH = 7.4) for 2.5 min at 4°C and stopped with MACS buffer (PBS, 0.5% bovine serum albumin (BSA), 2 mM EDTA). For fluorescence-activated cell sorting, cells were washed with PBS and stained with Fixable Viability Stain 700 (BD Biosciences) in PBS for 20 min at 4°C in the dark to exclude dead cells. Cell suspension was washed in PBS. Cells were stained with CD45-APC/Cy7 (clone 30F11, BioLegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312981">AB_312981</ext-link>), CD3-BV605 (clone 17A2, BioLegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2562039">AB_2562039</ext-link>), CD4-FITC (clone GK 1.5, BioLegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312691">AB_312691</ext-link>), CD8-Pacific Blue (clone 53-6.7, BioLegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493425">AB_493425</ext-link>), and CD19-PE/Cy7 (clone 1D3, BD; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10894021">AB_10894021</ext-link>) or with CD45-APC/Cy7 (clone 30F11, BioLegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312981">AB_312981</ext-link>), CD3-BV605 (clone 17A2, BioLegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2562039">AB_2562039</ext-link>), CD19-BV605 (clone 6D5, BioLegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11203538">AB_11203538</ext-link>), Ly6G-BV711 (clone 1A8, BD; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2738520">AB_2738520</ext-link>), F4/80-BV421 (clone T45-2342, BD; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2734779">AB_2734779</ext-link>), NK1.1- PE/Cy7 (clone PK136, BioLegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_389364">AB_389364</ext-link>), and CD11b-FITC (clone M1/70, BioLegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312789">AB_312789</ext-link>) in FACS buffer (PBS, 0.5% BSA, 0.02% NaN<sub>3</sub>) supplemented with Fc-Block (True Stain anti-mouse CD16/32, clone 93; BioLegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1574975">AB_1574975</ext-link>) for 30 min at 4°C in the dark, washed with PBS, and filtered and resuspended in PBS with 10 µM EDTA. CD4+ T cells (CD45+CD3+CD4+), CD8+ T cells (CD45+CD3+CD8+), B cells (CD45+CD19+), and macrophages (CD45+CD3-CD19- Ly6G-NK1.1-CD11b+ F4/80+) were sorted into collection tubes coated with FCS and filled with complete RPMI 1640 medium (1% penicillin, streptomycin, 0.1% 2-ME) with 20% FCS using a FACSAria device (BD Biosciences). Purity of sorted populations was routinely above 95%. Then cells were pelleted by centrifugation at 300 × <italic>g</italic> for 10 min at 4°C, dry frozen in liquid nitrogen, and stored at –80°C until RNA isolation. For isolation of microglia, mice were intracardially perfused with ice-cold PBS immediately after killing by inhalation of CO<sub>2</sub> to remove blood from intracranial vessels. Brain and spinal cord were excised with sterile instruments, and mechanically dissected and incubated with agitation in RPMI medium 1640 (PAN-Biotech) containing 1 mg/ml collagenase A (Roche) and 0.1 mg/ml DNaseI (Merck) for 60 min at 37°C. Tissue was triturated through a 40 μm cell strainer and washed with PBS (300 × <italic>g</italic>, 10 min, 4°C). Homogenized tissue was resuspended in 30% isotonic Percoll (GE Healthcare, Chicago, USA) and underlaid with 78% isotonic Percoll. After gradient centrifugation (1500 × <italic>g</italic>, 30 min, 4°C), CNS-immune cells were recovered from the gradient interphase and washed twice in ice-cold PBS. For fluorescence-activated cell sorting, cell suspensions were stained with Fixable Viability Stain 700, followed by staining of surface antigens with CD45-APC/Cy7 (clone 30F11, Biolegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312981">AB_312981</ext-link>), and CD11b-PerCPCy5.5 (clone M1/70, Biolegend; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312981">AB_312981</ext-link>) and Fc-Block as described above. Microglia (CD45med CD11b+) were sorted and processed for RNA isolation as described above.</p></sec><sec id="s4-16"><title>Quantitative real-time PCR</title><p>RNA was purified using the RNeasy Mini Kit (Qiagen) and reverse transcribed to cDNA with the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Fisher) according to the manufacturer’s instructions. Gene expression was analyzed by quantitative real-time PCR performed in an ABI Prism 7900 HT Fast Real-Time PCR System (Applied Biosystems, Waltham, USA) using TaqMan Gene Expression Assays (Thermo Fisher) for <italic>Ppargc1a</italic> (<italic>Pgc-1α</italic>; Mm00464452_m1), <italic>Alas</italic> (Mm01235914_m1), <italic>Cox4i1</italic> (Mm01250094_m1), <italic>Cs</italic> (Mm00466043_m1), <italic>Nrf1</italic> (Mm01135606_m1), <italic>Tfam</italic> (Mm00447485_m1), and <italic>Tbp</italic> (Mm01277042_m1). Gene expression was calculated as 2<sup>−ΔCT</sup> relative to <italic>Tbp</italic> as endogenous control.</p></sec><sec id="s4-17"><title>mtDNA copy number quantification</title><p>DNA was purified using the DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer’s instructions. To destroy RNA, samples were treated with RNAse (Qiagen). Mitochondrial DNA copy numbers relative to diploid chromosomal DNA content were analyzed by quantitative real-time PCR performed in an ABI Prism 7900 HT Fast Real-Time PCR System (Applied Biosystems) using TaqMan Gene Expression Assays (Thermo Fisher) for <italic>Cox2I</italic> (Mm03294838_g1) and <italic>β-actin</italic> (Mm_00607939_s1). MtDNA copy numbers were quantified as 2<sup>−ΔCT</sup> relative to β-actin.</p></sec><sec id="s4-18"><title><italic>Ppargc1a</italic> DNA copy number quantification</title><p>DNA was lysed with 50 µl QuickExtract DNA Extraction Solution (Lucigen, Middleton, USA). Copy numbers were analyzed by quantitative real-time PCR performed in an ABI Prism 7900 HT Fast Real-Time PCR System (Applied Biosystems) using TaqMan Copy Number Assays (Thermo Fisher) for <italic>Ppargc1a</italic> (<italic>Pgc-1α,</italic> Mm00164544_cn, FAM) and <italic>Tfrc</italic> (TaqMan Copy Number reference assay for mouse, VIC) in a duplex PCR. <italic>Ppargc1a</italic> copy numbers were quantified as 2<sup>−ΔCT</sup> relative to <italic>Tfrc</italic>.</p></sec><sec id="s4-19"><title>Immunoblot (Western Blot, WB)</title><p>After dissection, 15 mg of mouse spinal cord were lysed in 500 μl RIPA buffer supplemented with 50× protease inhibitor (complete, Sigma-Aldrich) and 2% 50x phosphatase (PhosSTOP, Sigma Aldrich), homogenized and incubated at 4°C for 30 min on a rotating wheel (GLW Storing Systems GmbH), and subsequently centrifuged at 3200 × <italic>g</italic> for 5 min at 4°C. Respective total protein amount of supernatant was determined with bicinchoninic acid protein assay. Only for validation of antibodies lambda protein phosphatase (New England BioLabs Inc, Ipswich, USA) was added to the samples. Samples were denatured by boiling 12 μg protein in a mixture of 15 μl 4× NuPAGE sample buffer (novex), 6 μl 10× Bolt sample reducing agent (novex), and RIPA buffer in a total volume of 60 μl for 5 min at 95°C. Samples were then loaded onto a Bolt 4–12% Bis-Tris Plus Gel (Invitrogen) in a Mini Gel Tank (Life Technologies, Carlsbad, USA). Chambers were filled with 1× Bolt MOPS SDS running buffer. Proteins were separated at 165 V for 1 hr. Spectra Multicolor High Range Protein Ladder (Thermo Fisher) was used as a protein standard. Proteins were then transferred to a nitrocellulose membrane at 10 V for 1 hr. For immunodetection, membrane was first blocked in 5% BSA in 1× TBS-T for 1 hr at room temperature and then incubated overnight at 4°C on a rotation wheel in 5% BSA in 1× TBS-T containing the primary antibodies against the following proteins: PGC-1α (rabbit 1:2000; Novus Biologicals; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1522118">AB_1522118</ext-link>), ﻿phosphorylated PGC-1αS570 (rabbit 1:1000; R and D Systems, Minneapolis, USA; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10890391">AB_10890391</ext-link>), and β-actin (rabbit 1:1000; Cell Signaling Technology, Cambridge, UK; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330288">AB_330288</ext-link>). The membrane was washed thrice with 1× TBS-T for 5 min each and subsequently incubated for 1 hr at RT on a shaker in 5% BSA in 1× TBS-T supplemented with a horseradish-peroxidase conjugated secondary antibody (goat 1:15000; LI-COR Biosciences, Lincoln, USA; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2721264">AB_2721264</ext-link>). The membrane was washed again three times in 1× TBS-T at RT for 5 min. Bound antibodies were detected by chemiluminescence using the WesternSure ECL Substrate (LI-COR Biosciences) using the CCD camera-based ImageQuant LAS 4000 Mini system (GE Healthcare).</p></sec><sec id="s4-20"><title>Statistics</title><p>No statistical methods were used to predetermine sample sizes; our sample sizes are similar to those reported in previous publications (<xref ref-type="bibr" rid="bib57">Schattling et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Schattling et al., 2012</xref>). Experimental data were analyzed using Prism 8 software (GraphPad) and are presented as mean values ± s.e.m. Statistical analyses were performed using the appropriate test indicated in the figure legends. Outlier identification was first performed via Grubb’s test with p=0.05. Shapiro–Wilk test was used to analyze normality. In normally distributed data, differences between two experimental groups were determined by unpaired, two-tailed Student's t-test; in non-normally distributed data, we tested differences between two experimental groups by unpaired, two-tailed Mann–Whitney test. Differences between three experimental groups were determined by multiple comparisons test following one-way ANOVA. Significant results are indicated by asterisk: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the UKE Mouse Pathology Facility for histopathology of EAE mice and the UKE Vector Facility for generating the calcium indicator viruses and the animal facility. We thank Hilmar Bading and Peter Bengtson for advice on calcium imaging. Funding SCR is supported by a Clinician-Scientist Fellowship from the Stifterverband für die Deutsche Wissenschaft and the Hertie Network of Excellence in Clinical Neuroscience of the Gemeinnützige Hertie-Stiftung. This work was supported by grants of the Deutsche Forschungsgemeinschaft (DFG) to MF (FR1638/3-1, FR1638/3-2) and MAF (FR1720/9-1, FR1720/9-2), which are part of the DFG FOR2289.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Software, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Software, Formal analysis, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Formal analysis, Funding acquisition, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Visualization, Methodology, Writing - original draft, Project administration</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: All animal care and experimental procedures were performed according to institutional guidelines and conformed to requirements of the German Animal Welfare Act. All animal experiments were approved by the local ethics committee (Behörde für Soziales, Familie, Gesundheit und Verbraucherschutz in Hamburg; G22/13 and 122/17). We conducted all procedures in accordance with the ARRIVE guidelines (Kilkenny et al., 2010).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-61798-transrepform-v3.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All current data have been provided. All individual data are reported within the figure graphs as scatter plots. Numerical data for Figure 3E, 5A and 5C can be found as Source Data. Enrichment analysis was performed using the function 'gseGO' of the R package clusterProfiler; plotting was performed with the R packages ggplot2, clusterProfiler and tidyheatmaps. Normalization, calcium spikes, base line detection, and analysis of the calcium clearance rate were performed with the custom-made script written on Python 3.6 (<ext-link ext-link-type="uri" xlink:href="https://github.com/scriptcalcium/PGC1alpha">https://github.com/scriptcalcium/PGC1alpha</ext-link>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:rev:af3c206a43f8b6e9fdbd7707c9b4601287d5968b/">https://archive.softwareheritage.org/swh:1:rev:af3c206a43f8b6e9fdbd7707c9b4601287d5968b/</ext-link>).</p><p>The following previously published dataset was used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Schattling</surname><given-names>B</given-names></name><name><surname>Engler</surname><given-names>JB</given-names></name><name><surname>Volkmann</surname><given-names>C</given-names></name><name><surname>Rothammer</surname><given-names>N</given-names></name><name><surname>Woo</surname><given-names>MS</given-names></name><name><surname>Petersen</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>I</given-names></name><name><surname>Kaufmann</surname><given-names>M</given-names></name><name><surname>Rosenkranz</surname><given-names>SC</given-names></name><name><surname>Fejtova</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>U</given-names></name><name><surname>Bose</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Träger</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>KK</given-names></name><name><surname>Brück</surname><given-names>W</given-names></name><name><surname>Duncan</surname><given-names>KE</given-names></name><name><surname>Salinas</surname><given-names>G</given-names></name><name><surname>Soba</surname><given-names>P</given-names></name><name><surname>Gundelfinger</surname><given-names>ED</given-names></name><name><surname>Merkler</surname><given-names>D</given-names></name><name><surname>Friese</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Bassoon proteinopathy drives neurodegeneration in multiple sclerosis</data-title><source>Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104899">GSE104899</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>HH</given-names></name><name><surname>Hibar</surname> <given-names>DP</given-names></name><name><surname>Chouraki</surname> <given-names>V</given-names></name><name><surname>Stein</surname> <given-names>JL</given-names></name><name><surname>Nyquist</surname> <given-names>PA</given-names></name><name><surname>Rentería</surname> <given-names>ME</given-names></name><name><surname>Trompet</surname> <given-names>S</given-names></name><name><surname>Arias-Vasquez</surname> <given-names>A</given-names></name><name><surname>Seshadri</surname> <given-names>S</given-names></name><name><surname>Desrivières</surname> <given-names>S</given-names></name><name><surname>Beecham</surname> <given-names>AH</given-names></name><name><surname>Jahanshad</surname> <given-names>N</given-names></name><name><surname>Wittfeld</surname> <given-names>K</given-names></name><name><surname>Van der Lee</surname> <given-names>SJ</given-names></name><name><surname>Abramovic</surname> <given-names>L</given-names></name><name><surname>Alhusaini</surname> <given-names>S</given-names></name><name><surname>Amin</surname> <given-names>N</given-names></name><name><surname>Andersson</surname> <given-names>M</given-names></name><name><surname>Arfanakis</surname> <given-names>K</given-names></name><name><surname>Aribisala</surname> <given-names>BS</given-names></name><name><surname>Armstrong</surname> <given-names>NJ</given-names></name><name><surname>Athanasiu</surname> <given-names>L</given-names></name><name><surname>Axelsson</surname> <given-names>T</given-names></name><name><surname>Beiser</surname> <given-names>A</given-names></name><name><surname>Bernard</surname> <given-names>M</given-names></name><name><surname>Bis</surname> <given-names>JC</given-names></name><name><surname>Blanken</surname> <given-names>LM</given-names></name><name><surname>Blanton</surname> <given-names>SH</given-names></name><name><surname>Bohlken</surname> <given-names>MM</given-names></name><name><surname>Boks</surname> <given-names>MP</given-names></name><name><surname>Bralten</surname> <given-names>J</given-names></name><name><surname>Brickman</surname> <given-names>AM</given-names></name><name><surname>Carmichael</surname> <given-names>O</given-names></name><name><surname>Chakravarty</surname> <given-names>MM</given-names></name><name><surname>Chauhan</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Ching</surname> <given-names>CR</given-names></name><name><surname>Cuellar-Partida</surname> <given-names>G</given-names></name><name><surname>Braber</surname> <given-names>AD</given-names></name><name><surname>Doan</surname> <given-names>NT</given-names></name><name><surname>Ehrlich</surname> <given-names>S</given-names></name><name><surname>Filippi</surname> <given-names>I</given-names></name><name><surname>Ge</surname> <given-names>T</given-names></name><name><surname>Giddaluru</surname> <given-names>S</given-names></name><name><surname>Goldman</surname> <given-names>AL</given-names></name><name><surname>Gottesman</surname> <given-names>RF</given-names></name><name><surname>Greven</surname> <given-names>CU</given-names></name><name><surname>Grimm</surname> <given-names>O</given-names></name><name><surname>Griswold</surname> <given-names>ME</given-names></name><name><surname>Guadalupe</surname> <given-names>T</given-names></name><name><surname>Hass</surname> <given-names>J</given-names></name><name><surname>Haukvik</surname> <given-names>UK</given-names></name><name><surname>Hilal</surname> <given-names>S</given-names></name><name><surname>Hofer</surname> <given-names>E</given-names></name><name><surname>Hoehn</surname> <given-names>D</given-names></name><name><surname>Holmes</surname> <given-names>AJ</given-names></name><name><surname>Hoogman</surname> <given-names>M</given-names></name><name><surname>Janowitz</surname> <given-names>D</given-names></name><name><surname>Jia</surname> <given-names>T</given-names></name><name><surname>Kasperaviciute</surname> <given-names>D</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Klein</surname> <given-names>M</given-names></name><name><surname>Kraemer</surname> <given-names>B</given-names></name><name><surname>Lee</surname> <given-names>PH</given-names></name><name><surname>Liao</surname> <given-names>J</given-names></name><name><surname>Liewald</surname> <given-names>DC</given-names></name><name><surname>Lopez</surname> <given-names>LM</given-names></name><name><surname>Luciano</surname> <given-names>M</given-names></name><name><surname>Macare</surname> <given-names>C</given-names></name><name><surname>Marquand</surname> <given-names>A</given-names></name><name><surname>Matarin</surname> <given-names>M</given-names></name><name><surname>Mather</surname> <given-names>KA</given-names></name><name><surname>Mattheisen</surname> <given-names>M</given-names></name><name><surname>Mazoyer</surname> <given-names>B</given-names></name><name><surname>McKay</surname> <given-names>DR</given-names></name><name><surname>McWhirter</surname> <given-names>R</given-names></name><name><surname>Milaneschi</surname> <given-names>Y</given-names></name><name><surname>Mirza-Schreiber</surname> <given-names>N</given-names></name><name><surname>Muetzel</surname> <given-names>RL</given-names></name><name><surname>Maniega</surname> <given-names>SM</given-names></name><name><surname>Nho</surname> <given-names>K</given-names></name><name><surname>Nugent</surname> <given-names>AC</given-names></name><name><surname>Loohuis</surname> <given-names>LM</given-names></name><name><surname>Oosterlaan</surname> <given-names>J</given-names></name><name><surname>Papmeyer</surname> <given-names>M</given-names></name><name><surname>Pappa</surname> <given-names>I</given-names></name><name><surname>Pirpamer</surname> <given-names>L</given-names></name><name><surname>Pudas</surname> <given-names>S</given-names></name><name><surname>Pütz</surname> <given-names>B</given-names></name><name><surname>Rajan</surname> <given-names>KB</given-names></name><name><surname>Ramasamy</surname> <given-names>A</given-names></name><name><surname>Richards</surname> <given-names>JS</given-names></name><name><surname>Risacher</surname> <given-names>SL</given-names></name><name><surname>Roiz-Santiañez</surname> <given-names>R</given-names></name><name><surname>Rommelse</surname> <given-names>N</given-names></name><name><surname>Rose</surname> <given-names>EJ</given-names></name><name><surname>Royle</surname> <given-names>NA</given-names></name><name><surname>Rundek</surname> <given-names>T</given-names></name><name><surname>Sämann</surname> <given-names>PG</given-names></name><name><surname>Satizabal</surname> <given-names>CL</given-names></name><name><surname>Schmaal</surname> <given-names>L</given-names></name><name><surname>Schork</surname> <given-names>AJ</given-names></name><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Shin</surname> <given-names>J</given-names></name><name><surname>Shumskaya</surname> <given-names>E</given-names></name><name><surname>Smith</surname> <given-names>AV</given-names></name><name><surname>Sprooten</surname> <given-names>E</given-names></name><name><surname>Strike</surname> <given-names>LT</given-names></name><name><surname>Teumer</surname> <given-names>A</given-names></name><name><surname>Thomson</surname> <given-names>R</given-names></name><name><surname>Tordesillas-Gutierrez</surname> <given-names>D</given-names></name><name><surname>Toro</surname> <given-names>R</given-names></name><name><surname>Trabzuni</surname> <given-names>D</given-names></name><name><surname>Vaidya</surname> <given-names>D</given-names></name><name><surname>Van der Grond</surname> <given-names>J</given-names></name><name><surname>Van der Meer</surname> <given-names>D</given-names></name><name><surname>Van Donkelaar</surname> <given-names>MM</given-names></name><name><surname>Van Eijk</surname> <given-names>KR</given-names></name><name><surname>Van Erp</surname> <given-names>TG</given-names></name><name><surname>Van Rooij</surname> <given-names>D</given-names></name><name><surname>Walton</surname> <given-names>E</given-names></name><name><surname>Westlye</surname> <given-names>LT</given-names></name><name><surname>Whelan</surname> <given-names>CD</given-names></name><name><surname>Windham</surname> <given-names>BG</given-names></name><name><surname>Winkler</surname> <given-names>AM</given-names></name><name><surname>Woldehawariat</surname> <given-names>G</given-names></name><name><surname>Wolf</surname> <given-names>C</given-names></name><name><surname>Wolfers</surname> <given-names>T</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Yanek</surname> <given-names>LR</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Zijdenbos</surname> <given-names>A</given-names></name><name><surname>Zwiers</surname> <given-names>MP</given-names></name><name><surname>Agartz</surname> <given-names>I</given-names></name><name><surname>Aggarwal</surname> <given-names>NT</given-names></name><name><surname>Almasy</surname> <given-names>L</given-names></name><name><surname>Ames</surname> <given-names>D</given-names></name><name><surname>Amouyel</surname> <given-names>P</given-names></name><name><surname>Andreassen</surname> <given-names>OA</given-names></name><name><surname>Arepalli</surname> <given-names>S</given-names></name><name><surname>Assareh</surname> <given-names>AA</given-names></name><name><surname>Barral</surname> <given-names>S</given-names></name><name><surname>Bastin</surname> <given-names>ME</given-names></name><name><surname>Becker</surname> <given-names>DM</given-names></name><name><surname>Becker</surname> <given-names>JT</given-names></name><name><surname>Bennett</surname> <given-names>DA</given-names></name><name><surname>Blangero</surname> <given-names>J</given-names></name><name><surname>van Bokhoven</surname> <given-names>H</given-names></name><name><surname>Boomsma</surname> <given-names>DI</given-names></name><name><surname>Brodaty</surname> <given-names>H</given-names></name><name><surname>Brouwer</surname> <given-names>RM</given-names></name><name><surname>Brunner</surname> <given-names>HG</given-names></name><name><surname>Buckner</surname> <given-names>RL</given-names></name><name><surname>Buitelaar</surname> <given-names>JK</given-names></name><name><surname>Bulayeva</surname> <given-names>KB</given-names></name><name><surname>Cahn</surname> <given-names>W</given-names></name><name><surname>Calhoun</surname> <given-names>VD</given-names></name><name><surname>Cannon</surname> <given-names>DM</given-names></name><name><surname>Cavalleri</surname> <given-names>GL</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Cheng</surname> <given-names>CY</given-names></name><name><surname>Cichon</surname> <given-names>S</given-names></name><name><surname>Cookson</surname> <given-names>MR</given-names></name><name><surname>Corvin</surname> <given-names>A</given-names></name><name><surname>Crespo-Facorro</surname> <given-names>B</given-names></name><name><surname>Curran</surname> <given-names>JE</given-names></name><name><surname>Czisch</surname> <given-names>M</given-names></name><name><surname>Dale</surname> <given-names>AM</given-names></name><name><surname>Davies</surname> <given-names>GE</given-names></name><name><surname>De Geus</surname> <given-names>EJ</given-names></name><name><surname>De Jager</surname> <given-names>PL</given-names></name><name><surname>de Zubicaray</surname> <given-names>GI</given-names></name><name><surname>Delanty</surname> <given-names>N</given-names></name><name><surname>Depondt</surname> <given-names>C</given-names></name><name><surname>DeStefano</surname> <given-names>AL</given-names></name><name><surname>Dillman</surname> <given-names>A</given-names></name><name><surname>Djurovic</surname> <given-names>S</given-names></name><name><surname>Donohoe</surname> <given-names>G</given-names></name><name><surname>Drevets</surname> <given-names>WC</given-names></name><name><surname>Duggirala</surname> <given-names>R</given-names></name><name><surname>Dyer</surname> <given-names>TD</given-names></name><name><surname>Erk</surname> <given-names>S</given-names></name><name><surname>Espeseth</surname> <given-names>T</given-names></name><name><surname>Evans</surname> <given-names>DA</given-names></name><name><surname>Fedko</surname> <given-names>IO</given-names></name><name><surname>Fernández</surname> <given-names>G</given-names></name><name><surname>Ferrucci</surname> <given-names>L</given-names></name><name><surname>Fisher</surname> <given-names>SE</given-names></name><name><surname>Fleischman</surname> <given-names>DA</given-names></name><name><surname>Ford</surname> <given-names>I</given-names></name><name><surname>Foroud</surname> <given-names>TM</given-names></name><name><surname>Fox</surname> <given-names>PT</given-names></name><name><surname>Francks</surname> <given-names>C</given-names></name><name><surname>Fukunaga</surname> <given-names>M</given-names></name><name><surname>Gibbs</surname> <given-names>JR</given-names></name><name><surname>Glahn</surname> <given-names>DC</given-names></name><name><surname>Gollub</surname> <given-names>RL</given-names></name><name><surname>Göring</surname> <given-names>HH</given-names></name><name><surname>Grabe</surname> <given-names>HJ</given-names></name><name><surname>Green</surname> <given-names>RC</given-names></name><name><surname>Gruber</surname> <given-names>O</given-names></name><name><surname>Gudnason</surname> <given-names>V</given-names></name><name><surname>Guelfi</surname> <given-names>S</given-names></name><name><surname>Hansell</surname> <given-names>NK</given-names></name><name><surname>Hardy</surname> <given-names>J</given-names></name><name><surname>Hartman</surname> <given-names>CA</given-names></name><name><surname>Hashimoto</surname> <given-names>R</given-names></name><name><surname>Hegenscheid</surname> <given-names>K</given-names></name><name><surname>Heinz</surname> <given-names>A</given-names></name><name><surname>Le Hellard</surname> <given-names>S</given-names></name><name><surname>Hernandez</surname> <given-names>DG</given-names></name><name><surname>Heslenfeld</surname> <given-names>DJ</given-names></name><name><surname>Ho</surname> <given-names>BC</given-names></name><name><surname>Hoekstra</surname> <given-names>PJ</given-names></name><name><surname>Hoffmann</surname> <given-names>W</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Holsboer</surname> <given-names>F</given-names></name><name><surname>Homuth</surname> <given-names>G</given-names></name><name><surname>Hosten</surname> <given-names>N</given-names></name><name><surname>Hottenga</surname> <given-names>JJ</given-names></name><name><surname>Hulshoff Pol</surname> <given-names>HE</given-names></name><name><surname>Ikeda</surname> <given-names>M</given-names></name><name><surname>Ikram</surname> <given-names>MK</given-names></name><name><surname>Jack</surname> <given-names>CR</given-names></name><name><surname>Jenkinson</surname> <given-names>M</given-names></name><name><surname>Johnson</surname> <given-names>R</given-names></name><name><surname>Jönsson</surname> <given-names>EG</given-names></name><name><surname>Jukema</surname> <given-names>JW</given-names></name><name><surname>Kahn</surname> <given-names>RS</given-names></name><name><surname>Kanai</surname> <given-names>R</given-names></name><name><surname>Kloszewska</surname> <given-names>I</given-names></name><name><surname>Knopman</surname> <given-names>DS</given-names></name><name><surname>Kochunov</surname> <given-names>P</given-names></name><name><surname>Kwok</surname> <given-names>JB</given-names></name><name><surname>Lawrie</surname> <given-names>SM</given-names></name><name><surname>Lemaître</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Longo</surname> <given-names>DL</given-names></name><name><surname>Longstreth</surname> <given-names>WT</given-names></name><name><surname>Lopez</surname> <given-names>OL</given-names></name><name><surname>Lovestone</surname> <given-names>S</given-names></name><name><surname>Martinez</surname> <given-names>O</given-names></name><name><surname>Martinot</surname> <given-names>JL</given-names></name><name><surname>Mattay</surname> <given-names>VS</given-names></name><name><surname>McDonald</surname> <given-names>C</given-names></name><name><surname>McIntosh</surname> <given-names>AM</given-names></name><name><surname>McMahon</surname> <given-names>KL</given-names></name><name><surname>McMahon</surname> <given-names>FJ</given-names></name><name><surname>Mecocci</surname> <given-names>P</given-names></name><name><surname>Melle</surname> <given-names>I</given-names></name><name><surname>Meyer-Lindenberg</surname> <given-names>A</given-names></name><name><surname>Mohnke</surname> <given-names>S</given-names></name><name><surname>Montgomery</surname> <given-names>GW</given-names></name><name><surname>Morris</surname> <given-names>DW</given-names></name><name><surname>Mosley</surname> <given-names>TH</given-names></name><name><surname>Mühleisen</surname> <given-names>TW</given-names></name><name><surname>Müller-Myhsok</surname> <given-names>B</given-names></name><name><surname>Nalls</surname> <given-names>MA</given-names></name><name><surname>Nauck</surname> <given-names>M</given-names></name><name><surname>Nichols</surname> <given-names>TE</given-names></name><name><surname>Niessen</surname> <given-names>WJ</given-names></name><name><surname>Nöthen</surname> <given-names>MM</given-names></name><name><surname>Nyberg</surname> <given-names>L</given-names></name><name><surname>Ohi</surname> <given-names>K</given-names></name><name><surname>Olvera</surname> <given-names>RL</given-names></name><name><surname>Ophoff</surname> <given-names>RA</given-names></name><name><surname>Pandolfo</surname> <given-names>M</given-names></name><name><surname>Paus</surname> <given-names>T</given-names></name><name><surname>Pausova</surname> <given-names>Z</given-names></name><name><surname>Penninx</surname> <given-names>BW</given-names></name><name><surname>Pike</surname> <given-names>GB</given-names></name><name><surname>Potkin</surname> <given-names>SG</given-names></name><name><surname>Psaty</surname> <given-names>BM</given-names></name><name><surname>Reppermund</surname> <given-names>S</given-names></name><name><surname>Rietschel</surname> <given-names>M</given-names></name><name><surname>Roffman</surname> <given-names>JL</given-names></name><name><surname>Romanczuk-Seiferth</surname> <given-names>N</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Ryten</surname> <given-names>M</given-names></name><name><surname>Sacco</surname> <given-names>RL</given-names></name><name><surname>Sachdev</surname> <given-names>PS</given-names></name><name><surname>Saykin</surname> <given-names>AJ</given-names></name><name><surname>Schmidt</surname> <given-names>R</given-names></name><name><surname>Schofield</surname> <given-names>PR</given-names></name><name><surname>Sigurdsson</surname> <given-names>S</given-names></name><name><surname>Simmons</surname> <given-names>A</given-names></name><name><surname>Singleton</surname> <given-names>A</given-names></name><name><surname>Sisodiya</surname> <given-names>SM</given-names></name><name><surname>Smith</surname> <given-names>C</given-names></name><name><surname>Smoller</surname> <given-names>JW</given-names></name><name><surname>Soininen</surname> <given-names>H</given-names></name><name><surname>Srikanth</surname> <given-names>V</given-names></name><name><surname>Steen</surname> <given-names>VM</given-names></name><name><surname>Stott</surname> <given-names>DJ</given-names></name><name><surname>Sussmann</surname> <given-names>JE</given-names></name><name><surname>Thalamuthu</surname> <given-names>A</given-names></name><name><surname>Tiemeier</surname> <given-names>H</given-names></name><name><surname>Toga</surname> <given-names>AW</given-names></name><name><surname>Traynor</surname> <given-names>BJ</given-names></name><name><surname>Troncoso</surname> <given-names>J</given-names></name><name><surname>Turner</surname> <given-names>JA</given-names></name><name><surname>Tzourio</surname> <given-names>C</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>Hernández</surname> <given-names>MC</given-names></name><name><surname>Van der Brug</surname> <given-names>M</given-names></name><name><surname>Van der Lugt</surname> <given-names>A</given-names></name><name><surname>Van der Wee</surname> <given-names>NJ</given-names></name><name><surname>Van Duijn</surname> <given-names>CM</given-names></name><name><surname>Van Haren</surname> <given-names>NE</given-names></name><name><surname>Van T Ent</surname> <given-names>D</given-names></name><name><surname>Van Tol</surname> <given-names>MJ</given-names></name><name><surname>Vardarajan</surname> <given-names>BN</given-names></name><name><surname>Veltman</surname> <given-names>DJ</given-names></name><name><surname>Vernooij</surname> <given-names>MW</given-names></name><name><surname>Völzke</surname> <given-names>H</given-names></name><name><surname>Walter</surname> <given-names>H</given-names></name><name><surname>Wardlaw</surname> <given-names>JM</given-names></name><name><surname>Wassink</surname> <given-names>TH</given-names></name><name><surname>Weale</surname> <given-names>ME</given-names></name><name><surname>Weinberger</surname> <given-names>DR</given-names></name><name><surname>Weiner</surname> <given-names>MW</given-names></name><name><surname>Wen</surname> <given-names>W</given-names></name><name><surname>Westman</surname> <given-names>E</given-names></name><name><surname>White</surname> <given-names>T</given-names></name><name><surname>Wong</surname> <given-names>TY</given-names></name><name><surname>Wright</surname> <given-names>CB</given-names></name><name><surname>Zielke</surname> <given-names>HR</given-names></name><name><surname>Zonderman</surname> <given-names>AB</given-names></name><name><surname>Deary</surname> <given-names>IJ</given-names></name><name><surname>DeCarli</surname> <given-names>C</given-names></name><name><surname>Schmidt</surname> <given-names>H</given-names></name><name><surname>Martin</surname> <given-names>NG</given-names></name><name><surname>De Craen</surname> <given-names>AJ</given-names></name><name><surname>Wright</surname> <given-names>MJ</given-names></name><name><surname>Launer</surname> <given-names>LJ</given-names></name><name><surname>Schumann</surname> <given-names>G</given-names></name><name><surname>Fornage</surname> <given-names>M</given-names></name><name><surname>Franke</surname> <given-names>B</given-names></name><name><surname>Debette</surname> <given-names>S</given-names></name><name><surname>Medland</surname> <given-names>SE</given-names></name><name><surname>Ikram</surname> <given-names>MA</given-names></name><name><surname>Thompson</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Novel genetic loci underlying human intracranial volume identified through genome-wide association</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>1569</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1038/nn.4398</pub-id><pub-id pub-id-type="pmid">27694991</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunet</surname> <given-names>A</given-names></name><name><surname>Bonni</surname> <given-names>A</given-names></name><name><surname>Zigmond</surname> <given-names>MJ</given-names></name><name><surname>Lin</surname> <given-names>MZ</given-names></name><name><surname>Juo</surname> <given-names>P</given-names></name><name><surname>Hu</surname> <given-names>LS</given-names></name><name><surname>Anderson</surname> <given-names>MJ</given-names></name><name><surname>Arden</surname> <given-names>KC</given-names></name><name><surname>Blenis</surname> <given-names>J</given-names></name><name><surname>Greenberg</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor</article-title><source>Cell</source><volume>96</volume><fpage>857</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80595-4</pub-id><pub-id pub-id-type="pmid">10102273</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname> <given-names>MD</given-names></name><name><surname>O'Sullivan</surname> <given-names>D</given-names></name><name><surname>Klein Geltink</surname> <given-names>RI</given-names></name><name><surname>Curtis</surname> <given-names>JD</given-names></name><name><surname>Chang</surname> <given-names>CH</given-names></name><name><surname>Sanin</surname> <given-names>DE</given-names></name><name><surname>Qiu</surname> <given-names>J</given-names></name><name><surname>Kretz</surname> <given-names>O</given-names></name><name><surname>Braas</surname> <given-names>D</given-names></name><name><surname>van der Windt</surname> <given-names>GJ</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Huang</surname> <given-names>SC</given-names></name><name><surname>O'Neill</surname> <given-names>CM</given-names></name><name><surname>Edelson</surname> <given-names>BT</given-names></name><name><surname>Pearce</surname> <given-names>EJ</given-names></name><name><surname>Sesaki</surname> <given-names>H</given-names></name><name><surname>Huber</surname> <given-names>TB</given-names></name><name><surname>Rambold</surname> <given-names>AS</given-names></name><name><surname>Pearce</surname> <given-names>EL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mitochondrial dynamics controls T cell fate through metabolic programming</article-title><source>Cell</source><volume>166</volume><fpage>63</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.05.035</pub-id><pub-id pub-id-type="pmid">27293185</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camandola</surname> <given-names>S</given-names></name><name><surname>Mattson</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Brain metabolism in health, aging, and neurodegeneration</article-title><source>The EMBO Journal</source><volume>36</volume><fpage>1474</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.15252/embj.201695810</pub-id><pub-id pub-id-type="pmid">28438892</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname> <given-names>GR</given-names></name><name><surname>Ziabreva</surname> <given-names>I</given-names></name><name><surname>Reeve</surname> <given-names>AK</given-names></name><name><surname>Krishnan</surname> <given-names>KJ</given-names></name><name><surname>Reynolds</surname> <given-names>R</given-names></name><name><surname>Howell</surname> <given-names>O</given-names></name><name><surname>Lassmann</surname> <given-names>H</given-names></name><name><surname>Turnbull</surname> <given-names>DM</given-names></name><name><surname>Mahad</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis</article-title><source>Annals of Neurology</source><volume>69</volume><fpage>481</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1002/ana.22109</pub-id><pub-id pub-id-type="pmid">21446022</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chataway</surname> <given-names>J</given-names></name><name><surname>De Angelis</surname> <given-names>F</given-names></name><name><surname>Connick</surname> <given-names>P</given-names></name><name><surname>Parker</surname> <given-names>RA</given-names></name><name><surname>Plantone</surname> <given-names>D</given-names></name><name><surname>Doshi</surname> <given-names>A</given-names></name><name><surname>John</surname> <given-names>N</given-names></name><name><surname>Stutters</surname> <given-names>J</given-names></name><name><surname>MacManus</surname> <given-names>D</given-names></name><name><surname>Prados Carrasco</surname> <given-names>F</given-names></name><name><surname>Barkhof</surname> <given-names>F</given-names></name><name><surname>Ourselin</surname> <given-names>S</given-names></name><name><surname>Braisher</surname> <given-names>M</given-names></name><name><surname>Ross</surname> <given-names>M</given-names></name><name><surname>Cranswick</surname> <given-names>G</given-names></name><name><surname>Pavitt</surname> <given-names>SH</given-names></name><name><surname>Giovannoni</surname> <given-names>G</given-names></name><name><surname>Gandini Wheeler-Kingshott</surname> <given-names>CA</given-names></name><name><surname>Hawkins</surname> <given-names>C</given-names></name><name><surname>Sharrack</surname> <given-names>B</given-names></name><name><surname>Bastow</surname> <given-names>R</given-names></name><name><surname>Weir</surname> <given-names>CJ</given-names></name><name><surname>Stallard</surname> <given-names>N</given-names></name><name><surname>Chandran</surname> <given-names>S</given-names></name><collab>MS-SMART Investigators</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial</article-title><source>The Lancet Neurology</source><volume>19</volume><fpage>214</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(19)30485-5</pub-id><pub-id pub-id-type="pmid">31981516</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craner</surname> <given-names>MJ</given-names></name><name><surname>Newcombe</surname> <given-names>J</given-names></name><name><surname>Black</surname> <given-names>JA</given-names></name><name><surname>Hartle</surname> <given-names>C</given-names></name><name><surname>Cuzner</surname> <given-names>ML</given-names></name><name><surname>Waxman</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger</article-title><source>PNAS</source><volume>101</volume><fpage>8168</fpage><lpage>8173</lpage><pub-id pub-id-type="doi">10.1073/pnas.0402765101</pub-id><pub-id pub-id-type="pmid">15148385</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname> <given-names>C</given-names></name><name><surname>Han</surname> <given-names>B</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Han</surname> <given-names>R</given-names></name><name><surname>Hao</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Up-regulation of PGC-1α in neurons protects against experimental autoimmune encephalomyelitis</article-title><source>The FASEB Journal</source><volume>33</volume><fpage>14811</fpage><lpage>14824</lpage><pub-id pub-id-type="doi">10.1096/fj.201901149RR</pub-id><pub-id pub-id-type="pmid">31718280</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dendrou</surname> <given-names>CA</given-names></name><name><surname>Fugger</surname> <given-names>L</given-names></name><name><surname>Friese</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Immunopathology of multiple sclerosis</article-title><source>Nature Reviews Immunology</source><volume>15</volume><fpage>545</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/nri3871</pub-id><pub-id pub-id-type="pmid">26250739</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumont</surname> <given-names>M</given-names></name><name><surname>Stack</surname> <given-names>C</given-names></name><name><surname>Elipenahli</surname> <given-names>C</given-names></name><name><surname>Jainuddin</surname> <given-names>S</given-names></name><name><surname>Gerges</surname> <given-names>M</given-names></name><name><surname>Starkova</surname> <given-names>N</given-names></name><name><surname>Calingasan</surname> <given-names>NY</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Tampellini</surname> <given-names>D</given-names></name><name><surname>Starkov</surname> <given-names>AA</given-names></name><name><surname>Chan</surname> <given-names>RB</given-names></name><name><surname>Di Paolo</surname> <given-names>G</given-names></name><name><surname>Pujol</surname> <given-names>A</given-names></name><name><surname>Beal</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice</article-title><source>Human Molecular Genetics</source><volume>21</volume><fpage>5091</fpage><lpage>5105</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds355</pub-id><pub-id pub-id-type="pmid">22922230</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Engler</surname> <given-names>JB</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>tidyheatmaps</data-title><source>GitHub</source><version designator="ed96130">ed96130</version><ext-link ext-link-type="uri" xlink:href="https://github.com/jbengler/tidyheatmaps">https://github.com/jbengler/tidyheatmaps</ext-link></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinstein</surname> <given-names>A</given-names></name><name><surname>Freeman</surname> <given-names>J</given-names></name><name><surname>Lo</surname> <given-names>AC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Treatment of progressive multiple sclerosis: what works, what does not, and what is needed</article-title><source>The Lancet Neurology</source><volume>14</volume><fpage>194</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(14)70231-5</pub-id><pub-id pub-id-type="pmid">25772898</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Marcos</surname> <given-names>PJ</given-names></name><name><surname>Auwerx</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis</article-title><source>The American Journal of Clinical Nutrition</source><volume>93</volume><fpage>884S</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.3945/ajcn.110.001917</pub-id><pub-id pub-id-type="pmid">21289221</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname> <given-names>E</given-names></name><name><surname>Lee</surname> <given-names>JC</given-names></name><name><surname>Nakamura</surname> <given-names>K</given-names></name><name><surname>Rudick</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Gray matter atrophy in multiple sclerosis: a longitudinal study</article-title><source>Annals of Neurology</source><volume>64</volume><fpage>255</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1002/ana.21436</pub-id><pub-id pub-id-type="pmid">18661561</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisniku</surname> <given-names>LK</given-names></name><name><surname>Chard</surname> <given-names>DT</given-names></name><name><surname>Jackson</surname> <given-names>JS</given-names></name><name><surname>Anderson</surname> <given-names>VM</given-names></name><name><surname>Altmann</surname> <given-names>DR</given-names></name><name><surname>Miszkiel</surname> <given-names>KA</given-names></name><name><surname>Thompson</surname> <given-names>AJ</given-names></name><name><surname>Miller</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Gray matter atrophy is related to long-term disability in multiple sclerosis</article-title><source>Annals of Neurology</source><volume>64</volume><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1002/ana.21423</pub-id><pub-id pub-id-type="pmid">18570297</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forte</surname> <given-names>M</given-names></name><name><surname>Gold</surname> <given-names>BG</given-names></name><name><surname>Marracci</surname> <given-names>G</given-names></name><name><surname>Chaudhary</surname> <given-names>P</given-names></name><name><surname>Basso</surname> <given-names>E</given-names></name><name><surname>Johnsen</surname> <given-names>D</given-names></name><name><surname>Yu</surname> <given-names>X</given-names></name><name><surname>Fowlkes</surname> <given-names>J</given-names></name><name><surname>Rahder</surname> <given-names>M</given-names></name><name><surname>Stem</surname> <given-names>K</given-names></name><name><surname>Bernardi</surname> <given-names>P</given-names></name><name><surname>Bourdette</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis</article-title><source>PNAS</source><volume>104</volume><fpage>7558</fpage><lpage>7563</lpage><pub-id pub-id-type="doi">10.1073/pnas.0702228104</pub-id><pub-id pub-id-type="pmid">17463082</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fournier</surname> <given-names>AP</given-names></name><name><surname>Quenault</surname> <given-names>A</given-names></name><name><surname>Martinez de Lizarrondo</surname> <given-names>S</given-names></name><name><surname>Gauberti</surname> <given-names>M</given-names></name><name><surname>Defer</surname> <given-names>G</given-names></name><name><surname>Vivien</surname> <given-names>D</given-names></name><name><surname>Docagne</surname> <given-names>F</given-names></name><name><surname>Macrez</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin</article-title><source>PNAS</source><volume>114</volume><fpage>6116</fpage><lpage>6121</lpage><pub-id pub-id-type="doi">10.1073/pnas.1619424114</pub-id><pub-id pub-id-type="pmid">28533365</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friese</surname> <given-names>MA</given-names></name><name><surname>Craner</surname> <given-names>MJ</given-names></name><name><surname>Etzensperger</surname> <given-names>R</given-names></name><name><surname>Vergo</surname> <given-names>S</given-names></name><name><surname>Wemmie</surname> <given-names>JA</given-names></name><name><surname>Welsh</surname> <given-names>MJ</given-names></name><name><surname>Vincent</surname> <given-names>A</given-names></name><name><surname>Fugger</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system</article-title><source>Nature Medicine</source><volume>13</volume><fpage>1483</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1038/nm1668</pub-id><pub-id pub-id-type="pmid">17994101</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friese</surname> <given-names>MA</given-names></name><name><surname>Schattling</surname> <given-names>B</given-names></name><name><surname>Fugger</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis</article-title><source>Nature Reviews Neurology</source><volume>10</volume><fpage>225</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.37</pub-id><pub-id pub-id-type="pmid">24638138</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgi</surname> <given-names>C</given-names></name><name><surname>Marchi</surname> <given-names>S</given-names></name><name><surname>Pinton</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The machineries, regulation and cellular functions of mitochondrial calcium</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>19</volume><fpage>713</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1038/s41580-018-0052-8</pub-id><pub-id pub-id-type="pmid">30143745</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>L</given-names></name><name><surname>Findley</surname> <given-names>HW</given-names></name><name><surname>Zhu</surname> <given-names>N</given-names></name><name><surname>Zhou</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Endogenous TNFalpha mediates cell survival and chemotherapy resistance by activating the PI3K/Akt pathway in acute lymphoblastic leukemia cells</article-title><source>Leukemia</source><volume>20</volume><fpage>900</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2404160</pub-id><pub-id pub-id-type="pmid">16511511</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heiman</surname> <given-names>M</given-names></name><name><surname>Schaefer</surname> <given-names>A</given-names></name><name><surname>Gong</surname> <given-names>S</given-names></name><name><surname>Peterson</surname> <given-names>JD</given-names></name><name><surname>Day</surname> <given-names>M</given-names></name><name><surname>Ramsey</surname> <given-names>KE</given-names></name><name><surname>Suárez-Fariñas</surname> <given-names>M</given-names></name><name><surname>Schwarz</surname> <given-names>C</given-names></name><name><surname>Stephan</surname> <given-names>DA</given-names></name><name><surname>Surmeier</surname> <given-names>DJ</given-names></name><name><surname>Greengard</surname> <given-names>P</given-names></name><name><surname>Heintz</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A translational profiling approach for the molecular characterization of CNS cell types</article-title><source>Cell</source><volume>135</volume><fpage>738</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.10.028</pub-id><pub-id pub-id-type="pmid">19013281</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heng</surname> <given-names>TS</given-names></name><name><surname>Painter</surname> <given-names>MW</given-names></name><collab>Immunological Genome Project Consortium</collab></person-group><year iso-8601-date="2008">2008</year><article-title>The immunological genome project: networks of gene expression in immune cells</article-title><source>Nature Immunology</source><volume>9</volume><fpage>1091</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/ni1008-1091</pub-id><pub-id pub-id-type="pmid">18800157</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofer</surname> <given-names>A</given-names></name><name><surname>Noe</surname> <given-names>N</given-names></name><name><surname>Tischner</surname> <given-names>C</given-names></name><name><surname>Kladt</surname> <given-names>N</given-names></name><name><surname>Lellek</surname> <given-names>V</given-names></name><name><surname>Schauß</surname> <given-names>A</given-names></name><name><surname>Wenz</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Defining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo</article-title><source>Human Molecular Genetics</source><volume>23</volume><fpage>2400</fpage><lpage>2415</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddt631</pub-id><pub-id pub-id-type="pmid">24334768</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kann</surname> <given-names>O</given-names></name><name><surname>Kovács</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mitochondria and neuronal activity</article-title><source>American Journal of Physiology-Cell Physiology</source><volume>292</volume><fpage>C641</fpage><lpage>C657</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00222.2006</pub-id><pub-id pub-id-type="pmid">17092996</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappos</surname> <given-names>L</given-names></name><name><surname>Bar-Or</surname> <given-names>A</given-names></name><name><surname>Cree</surname> <given-names>BAC</given-names></name><name><surname>Fox</surname> <given-names>RJ</given-names></name><name><surname>Giovannoni</surname> <given-names>G</given-names></name><name><surname>Gold</surname> <given-names>R</given-names></name><name><surname>Vermersch</surname> <given-names>P</given-names></name><name><surname>Arnold</surname> <given-names>DL</given-names></name><name><surname>Arnould</surname> <given-names>S</given-names></name><name><surname>Scherz</surname> <given-names>T</given-names></name><name><surname>Wolf</surname> <given-names>C</given-names></name><name><surname>Wallström</surname> <given-names>E</given-names></name><name><surname>Dahlke</surname> <given-names>F</given-names></name><collab>EXPAND Clinical Investigators</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study</article-title><source>The Lancet</source><volume>391</volume><fpage>1263</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)30475-6</pub-id><pub-id pub-id-type="pmid">29576505</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilkenny</surname> <given-names>C</given-names></name><name><surname>Browne</surname> <given-names>WJ</given-names></name><name><surname>Cuthill</surname> <given-names>IC</given-names></name><name><surname>Emerson</surname> <given-names>M</given-names></name><name><surname>Altman</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research</article-title><source>PLOS Biology</source><volume>8</volume><elocation-id>e1000412</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000412</pub-id><pub-id pub-id-type="pmid">20613859</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaren</surname> <given-names>RE</given-names></name><name><surname>Motl</surname> <given-names>RW</given-names></name><name><surname>Woods</surname> <given-names>JA</given-names></name><name><surname>Miller</surname> <given-names>SD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis)</article-title><source>Journal of Neuroimmunology</source><volume>274</volume><fpage>14</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2014.06.014</pub-id><pub-id pub-id-type="pmid">24999244</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>KS</given-names></name><name><surname>Huh</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>Z</given-names></name><name><surname>Kim</surname> <given-names>AK</given-names></name><name><surname>Kang</surname> <given-names>HY</given-names></name><name><surname>Lu</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Altered ER-mitochondria contact impacts mitochondria calcium homeostasis and contributes to neurodegeneration in vivo in disease models</article-title><source>PNAS</source><volume>115</volume><fpage>E8844</fpage><lpage>E8853</lpage><pub-id pub-id-type="doi">10.1073/pnas.1721136115</pub-id><pub-id pub-id-type="pmid">30185553</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levenga</surname> <given-names>J</given-names></name><name><surname>Wong</surname> <given-names>H</given-names></name><name><surname>Milstead</surname> <given-names>RA</given-names></name><name><surname>Keller</surname> <given-names>BN</given-names></name><name><surname>LaPlante</surname> <given-names>LE</given-names></name><name><surname>Hoeffer</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>AKT isoforms have distinct hippocampal expression and roles in synaptic plasticity</article-title><source>eLife</source><volume>6</volume><elocation-id>e30640</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.30640</pub-id><pub-id pub-id-type="pmid">29173281</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Monks</surname> <given-names>B</given-names></name><name><surname>Ge</surname> <given-names>Q</given-names></name><name><surname>Birnbaum</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator</article-title><source>Nature</source><volume>447</volume><fpage>1012</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1038/nature05861</pub-id><pub-id pub-id-type="pmid">17554339</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Gan</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Song</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Ouyang</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The inflammatory cytokine TNF-α promotes the premature senescence of rat nucleus pulposus cells via the PI3K/Akt signaling pathway</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>42938</elocation-id><pub-id pub-id-type="doi">10.1038/srep42938</pub-id><pub-id pub-id-type="pmid">28211497</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>PH</given-names></name><name><surname>Tarr</surname> <given-names>PT</given-names></name><name><surname>Lindenberg</surname> <given-names>KS</given-names></name><name><surname>St-Pierre</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>CY</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Jäger</surname> <given-names>S</given-names></name><name><surname>Vianna</surname> <given-names>CR</given-names></name><name><surname>Reznick</surname> <given-names>RM</given-names></name><name><surname>Cui</surname> <given-names>L</given-names></name><name><surname>Manieri</surname> <given-names>M</given-names></name><name><surname>Donovan</surname> <given-names>MX</given-names></name><name><surname>Wu</surname> <given-names>Z</given-names></name><name><surname>Cooper</surname> <given-names>MP</given-names></name><name><surname>Fan</surname> <given-names>MC</given-names></name><name><surname>Rohas</surname> <given-names>LM</given-names></name><name><surname>Zavacki</surname> <given-names>AM</given-names></name><name><surname>Cinti</surname> <given-names>S</given-names></name><name><surname>Shulman</surname> <given-names>GI</given-names></name><name><surname>Lowell</surname> <given-names>BB</given-names></name><name><surname>Krainc</surname> <given-names>D</given-names></name><name><surname>Spiegelman</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice</article-title><source>Cell</source><volume>119</volume><fpage>121</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.09.013</pub-id><pub-id pub-id-type="pmid">15454086</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Handschin</surname> <given-names>C</given-names></name><name><surname>Spiegelman</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Metabolic control through the PGC-1 family of transcription coactivators</article-title><source>Cell Metabolism</source><volume>1</volume><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2005.05.004</pub-id><pub-id pub-id-type="pmid">16054085</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname> <given-names>EK</given-names></name><name><surname>Dougherty</surname> <given-names>SE</given-names></name><name><surname>McMeekin</surname> <given-names>LJ</given-names></name><name><surname>Reid</surname> <given-names>CS</given-names></name><name><surname>Dobrunz</surname> <given-names>LE</given-names></name><name><surname>West</surname> <given-names>AB</given-names></name><name><surname>Hablitz</surname> <given-names>JJ</given-names></name><name><surname>Cowell</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PGC-1α provides a transcriptional framework for synchronous neurotransmitter release from parvalbumin-positive interneurons</article-title><source>Journal of Neuroscience</source><volume>34</volume><fpage>14375</fpage><lpage>14387</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1222-14.2014</pub-id><pub-id pub-id-type="pmid">25339750</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahad</surname> <given-names>DJ</given-names></name><name><surname>Ziabreva</surname> <given-names>I</given-names></name><name><surname>Campbell</surname> <given-names>G</given-names></name><name><surname>Lax</surname> <given-names>N</given-names></name><name><surname>White</surname> <given-names>K</given-names></name><name><surname>Hanson</surname> <given-names>PS</given-names></name><name><surname>Lassmann</surname> <given-names>H</given-names></name><name><surname>Turnbull</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mitochondrial changes within axons in multiple sclerosis</article-title><source>Brain</source><volume>132</volume><fpage>1161</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1093/brain/awp046</pub-id><pub-id pub-id-type="pmid">19293237</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattson</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Calcium and neurodegeneration</article-title><source>Aging Cell</source><volume>6</volume><fpage>337</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1111/j.1474-9726.2007.00275.x</pub-id><pub-id pub-id-type="pmid">17328689</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalban</surname> <given-names>X</given-names></name><name><surname>Hauser</surname> <given-names>SL</given-names></name><name><surname>Kappos</surname> <given-names>L</given-names></name><name><surname>Arnold</surname> <given-names>DL</given-names></name><name><surname>Bar-Or</surname> <given-names>A</given-names></name><name><surname>Comi</surname> <given-names>G</given-names></name><name><surname>de Seze</surname> <given-names>J</given-names></name><name><surname>Giovannoni</surname> <given-names>G</given-names></name><name><surname>Hartung</surname> <given-names>HP</given-names></name><name><surname>Hemmer</surname> <given-names>B</given-names></name><name><surname>Lublin</surname> <given-names>F</given-names></name><name><surname>Rammohan</surname> <given-names>KW</given-names></name><name><surname>Selmaj</surname> <given-names>K</given-names></name><name><surname>Traboulsee</surname> <given-names>A</given-names></name><name><surname>Sauter</surname> <given-names>A</given-names></name><name><surname>Masterman</surname> <given-names>D</given-names></name><name><surname>Fontoura</surname> <given-names>P</given-names></name><name><surname>Belachew</surname> <given-names>S</given-names></name><name><surname>Garren</surname> <given-names>H</given-names></name><name><surname>Mairon</surname> <given-names>N</given-names></name><name><surname>Chin</surname> <given-names>P</given-names></name><name><surname>Wolinsky</surname> <given-names>JS</given-names></name><collab>ORATORIO Clinical Investigators</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Ocrelizumab versus placebo in primary progressive multiple sclerosis</article-title><source>New England Journal of Medicine</source><volume>376</volume><fpage>209</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1606468</pub-id><pub-id pub-id-type="pmid">28002688</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Eriksson</surname> <given-names>KF</given-names></name><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Sihag</surname> <given-names>S</given-names></name><name><surname>Lehar</surname> <given-names>J</given-names></name><name><surname>Puigserver</surname> <given-names>P</given-names></name><name><surname>Carlsson</surname> <given-names>E</given-names></name><name><surname>Ridderstråle</surname> <given-names>M</given-names></name><name><surname>Laurila</surname> <given-names>E</given-names></name><name><surname>Houstis</surname> <given-names>N</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Patterson</surname> <given-names>N</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Spiegelman</surname> <given-names>B</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Groop</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes</article-title><source>Nature Genetics</source><volume>34</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/ng1180</pub-id><pub-id pub-id-type="pmid">12808457</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motl</surname> <given-names>RW</given-names></name><name><surname>Sandroff</surname> <given-names>BM</given-names></name><name><surname>Kwakkel</surname> <given-names>G</given-names></name><name><surname>Dalgas</surname> <given-names>U</given-names></name><name><surname>Feinstein</surname> <given-names>A</given-names></name><name><surname>Heesen</surname> <given-names>C</given-names></name><name><surname>Feys</surname> <given-names>P</given-names></name><name><surname>Thompson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Exercise in patients with multiple sclerosis</article-title><source>The Lancet Neurology</source><volume>16</volume><fpage>848</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(17)30281-8</pub-id><pub-id pub-id-type="pmid">28920890</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mudò</surname> <given-names>G</given-names></name><name><surname>Mäkelä</surname> <given-names>J</given-names></name><name><surname>Di Liberto</surname> <given-names>V</given-names></name><name><surname>Tselykh</surname> <given-names>TV</given-names></name><name><surname>Olivieri</surname> <given-names>M</given-names></name><name><surname>Piepponen</surname> <given-names>P</given-names></name><name><surname>Eriksson</surname> <given-names>O</given-names></name><name><surname>Mälkiä</surname> <given-names>A</given-names></name><name><surname>Bonomo</surname> <given-names>A</given-names></name><name><surname>Kairisalo</surname> <given-names>M</given-names></name><name><surname>Aguirre</surname> <given-names>JA</given-names></name><name><surname>Korhonen</surname> <given-names>L</given-names></name><name><surname>Belluardo</surname> <given-names>N</given-names></name><name><surname>Lindholm</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease</article-title><source>Cellular and Molecular Life Sciences</source><volume>69</volume><fpage>1153</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1007/s00018-011-0850-z</pub-id><pub-id pub-id-type="pmid">21984601</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname> <given-names>MP</given-names></name><name><surname>Hartley</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mitochondria as a therapeutic target for common pathologies</article-title><source>Nature Reviews Drug Discovery</source><volume>17</volume><fpage>865</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1038/nrd.2018.174</pub-id><pub-id pub-id-type="pmid">30393373</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikić</surname> <given-names>I</given-names></name><name><surname>Merkler</surname> <given-names>D</given-names></name><name><surname>Sorbara</surname> <given-names>C</given-names></name><name><surname>Brinkoetter</surname> <given-names>M</given-names></name><name><surname>Kreutzfeldt</surname> <given-names>M</given-names></name><name><surname>Bareyre</surname> <given-names>FM</given-names></name><name><surname>Brück</surname> <given-names>W</given-names></name><name><surname>Bishop</surname> <given-names>D</given-names></name><name><surname>Misgeld</surname> <given-names>T</given-names></name><name><surname>Kerschensteiner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis</article-title><source>Nature Medicine</source><volume>17</volume><fpage>495</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1038/nm.2324</pub-id><pub-id pub-id-type="pmid">21441916</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nimmagadda</surname> <given-names>VK</given-names></name><name><surname>Bever</surname> <given-names>CT</given-names></name><name><surname>Vattikunta</surname> <given-names>NR</given-names></name><name><surname>Talat</surname> <given-names>S</given-names></name><name><surname>Ahmad</surname> <given-names>V</given-names></name><name><surname>Nagalla</surname> <given-names>NK</given-names></name><name><surname>Trisler</surname> <given-names>D</given-names></name><name><surname>Judge</surname> <given-names>SI</given-names></name><name><surname>Royal</surname> <given-names>W</given-names></name><name><surname>Chandrasekaran</surname> <given-names>K</given-names></name><name><surname>Russell</surname> <given-names>JW</given-names></name><name><surname>Makar</surname> <given-names>TK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets</article-title><source>The Journal of Immunology</source><volume>190</volume><fpage>4595</fpage><lpage>4607</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202584</pub-id><pub-id pub-id-type="pmid">23547115</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noe</surname> <given-names>N</given-names></name><name><surname>Dillon</surname> <given-names>L</given-names></name><name><surname>Lellek</surname> <given-names>V</given-names></name><name><surname>Diaz</surname> <given-names>F</given-names></name><name><surname>Hida</surname> <given-names>A</given-names></name><name><surname>Moraes</surname> <given-names>CT</given-names></name><name><surname>Wenz</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>RETRACTED: bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy</article-title><source>Mitochondrion</source><volume>13</volume><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1016/j.mito.2012.12.003</pub-id><pub-id pub-id-type="pmid">23261681</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osawa</surname> <given-names>Y</given-names></name><name><surname>Banno</surname> <given-names>Y</given-names></name><name><surname>Nagaki</surname> <given-names>M</given-names></name><name><surname>Brenner</surname> <given-names>DA</given-names></name><name><surname>Naiki</surname> <given-names>T</given-names></name><name><surname>Nozawa</surname> <given-names>Y</given-names></name><name><surname>Nakashima</surname> <given-names>S</given-names></name><name><surname>Moriwaki</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>TNF-alpha-induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytes</article-title><source>The Journal of Immunology</source><volume>167</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.1.173</pub-id><pub-id pub-id-type="pmid">11418646</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pannaccione</surname> <given-names>A</given-names></name><name><surname>Piccialli</surname> <given-names>I</given-names></name><name><surname>Secondo</surname> <given-names>A</given-names></name><name><surname>Ciccone</surname> <given-names>R</given-names></name><name><surname>Molinaro</surname> <given-names>P</given-names></name><name><surname>Boscia</surname> <given-names>F</given-names></name><name><surname>Annunziato</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The na+/Ca2+exchanger in Alzheimer’s disease</article-title><source>Cell Calcium</source><volume>87</volume><elocation-id>102190</elocation-id><pub-id pub-id-type="doi">10.1016/j.ceca.2020.102190</pub-id><pub-id pub-id-type="pmid">32199208</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parone</surname> <given-names>PA</given-names></name><name><surname>Da Cruz</surname> <given-names>S</given-names></name><name><surname>Han</surname> <given-names>JS</given-names></name><name><surname>McAlonis-Downes</surname> <given-names>M</given-names></name><name><surname>Vetto</surname> <given-names>AP</given-names></name><name><surname>Lee</surname> <given-names>SK</given-names></name><name><surname>Tseng</surname> <given-names>E</given-names></name><name><surname>Cleveland</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis</article-title><source>Journal of Neuroscience</source><volume>33</volume><fpage>4657</fpage><lpage>4671</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1119-12.2013</pub-id><pub-id pub-id-type="pmid">23486940</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peltier</surname> <given-names>J</given-names></name><name><surname>O'Neill</surname> <given-names>A</given-names></name><name><surname>Schaffer</surname> <given-names>DV</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation</article-title><source>Developmental Neurobiology</source><volume>67</volume><fpage>1348</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1002/dneu.20506</pub-id><pub-id pub-id-type="pmid">17638387</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puigserver</surname> <given-names>P</given-names></name><name><surname>Wu</surname> <given-names>Z</given-names></name><name><surname>Park</surname> <given-names>CW</given-names></name><name><surname>Graves</surname> <given-names>R</given-names></name><name><surname>Wright</surname> <given-names>M</given-names></name><name><surname>Spiegelman</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis</article-title><source>Cell</source><volume>92</volume><fpage>829</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81410-5</pub-id><pub-id pub-id-type="pmid">9529258</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivière</surname> <given-names>JB</given-names></name><name><surname>Mirzaa</surname> <given-names>GM</given-names></name><name><surname>O'Roak</surname> <given-names>BJ</given-names></name><name><surname>Beddaoui</surname> <given-names>M</given-names></name><name><surname>Alcantara</surname> <given-names>D</given-names></name><name><surname>Conway</surname> <given-names>RL</given-names></name><name><surname>St-Onge</surname> <given-names>J</given-names></name><name><surname>Schwartzentruber</surname> <given-names>JA</given-names></name><name><surname>Gripp</surname> <given-names>KW</given-names></name><name><surname>Nikkel</surname> <given-names>SM</given-names></name><name><surname>Worthylake</surname> <given-names>T</given-names></name><name><surname>Sullivan</surname> <given-names>CT</given-names></name><name><surname>Ward</surname> <given-names>TR</given-names></name><name><surname>Butler</surname> <given-names>HE</given-names></name><name><surname>Kramer</surname> <given-names>NA</given-names></name><name><surname>Albrecht</surname> <given-names>B</given-names></name><name><surname>Armour</surname> <given-names>CM</given-names></name><name><surname>Armstrong</surname> <given-names>L</given-names></name><name><surname>Caluseriu</surname> <given-names>O</given-names></name><name><surname>Cytrynbaum</surname> <given-names>C</given-names></name><name><surname>Drolet</surname> <given-names>BA</given-names></name><name><surname>Innes</surname> <given-names>AM</given-names></name><name><surname>Lauzon</surname> <given-names>JL</given-names></name><name><surname>Lin</surname> <given-names>AE</given-names></name><name><surname>Mancini</surname> <given-names>GM</given-names></name><name><surname>Meschino</surname> <given-names>WS</given-names></name><name><surname>Reggin</surname> <given-names>JD</given-names></name><name><surname>Saggar</surname> <given-names>AK</given-names></name><name><surname>Lerman-Sagie</surname> <given-names>T</given-names></name><name><surname>Uyanik</surname> <given-names>G</given-names></name><name><surname>Weksberg</surname> <given-names>R</given-names></name><name><surname>Zirn</surname> <given-names>B</given-names></name><name><surname>Beaulieu</surname> <given-names>CL</given-names></name><name><surname>Majewski</surname> <given-names>J</given-names></name><name><surname>Bulman</surname> <given-names>DE</given-names></name><name><surname>O'Driscoll</surname> <given-names>M</given-names></name><name><surname>Shendure</surname> <given-names>J</given-names></name><name><surname>Graham</surname> <given-names>JM</given-names></name><name><surname>Boycott</surname> <given-names>KM</given-names></name><name><surname>Dobyns</surname> <given-names>WB</given-names></name><collab>Finding of Rare Disease Genes (FORGE) Canada Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes</article-title><source>Nature Genetics</source><volume>44</volume><fpage>934</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1038/ng.2331</pub-id><pub-id pub-id-type="pmid">22729224</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzuto</surname> <given-names>R</given-names></name><name><surname>De Stefani</surname> <given-names>D</given-names></name><name><surname>Raffaello</surname> <given-names>A</given-names></name><name><surname>Mammucari</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mitochondria as sensors and regulators of calcium signalling</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>13</volume><fpage>566</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1038/nrm3412</pub-id><pub-id pub-id-type="pmid">22850819</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Rosenkranz</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>PGC1alpha</data-title><source>Software Heritage</source><version designator="swh:1:rev:af3c206a43f8b6e9fdbd7707c9b4601287d5968b">swh:1:rev:af3c206a43f8b6e9fdbd7707c9b4601287d5968b</version><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:9be6b665fa6cd2a737362413f9eb929979d71921;origin=https://github.com/scriptcalcium/PGC1alpha;visit=swh:1:snp:e4c8a5fc8a6e6bbb6492e5c9fe440bca33866055;anchor=swh:1:rev:af3c206a43f8b6e9fdbd7707c9b4601287d5968b/">https://archive.softwareheritage.org/swh:1:dir:9be6b665fa6cd2a737362413f9eb929979d71921;origin=https://github.com/scriptcalcium/PGC1alpha;visit=swh:1:snp:e4c8a5fc8a6e6bbb6492e5c9fe440bca33866055;anchor=swh:1:rev:af3c206a43f8b6e9fdbd7707c9b4601287d5968b/</ext-link></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname> <given-names>S</given-names></name><name><surname>Furlan</surname> <given-names>R</given-names></name><name><surname>De Chiara</surname> <given-names>V</given-names></name><name><surname>Musella</surname> <given-names>A</given-names></name><name><surname>Lo Giudice</surname> <given-names>T</given-names></name><name><surname>Mataluni</surname> <given-names>G</given-names></name><name><surname>Cavasinni</surname> <given-names>F</given-names></name><name><surname>Cantarella</surname> <given-names>C</given-names></name><name><surname>Bernardi</surname> <given-names>G</given-names></name><name><surname>Muzio</surname> <given-names>L</given-names></name><name><surname>Martorana</surname> <given-names>A</given-names></name><name><surname>Martino</surname> <given-names>G</given-names></name><name><surname>Centonze</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis</article-title><source>Neurobiology of Disease</source><volume>36</volume><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2009.06.013</pub-id><pub-id pub-id-type="pmid">19591937</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadeghian</surname> <given-names>M</given-names></name><name><surname>Mastrolia</surname> <given-names>V</given-names></name><name><surname>Rezaei Haddad</surname> <given-names>A</given-names></name><name><surname>Mosley</surname> <given-names>A</given-names></name><name><surname>Mullali</surname> <given-names>G</given-names></name><name><surname>Schiza</surname> <given-names>D</given-names></name><name><surname>Sajic</surname> <given-names>M</given-names></name><name><surname>Hargreaves</surname> <given-names>I</given-names></name><name><surname>Heales</surname> <given-names>S</given-names></name><name><surname>Duchen</surname> <given-names>MR</given-names></name><name><surname>Smith</surname> <given-names>KJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mitochondrial dysfunction is an important cause of neurological deficits in an inflammatory model of multiple sclerosis</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>33249</elocation-id><pub-id pub-id-type="doi">10.1038/srep33249</pub-id><pub-id pub-id-type="pmid">27624721</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schattling</surname> <given-names>B</given-names></name><name><surname>Steinbach</surname> <given-names>K</given-names></name><name><surname>Thies</surname> <given-names>E</given-names></name><name><surname>Kruse</surname> <given-names>M</given-names></name><name><surname>Menigoz</surname> <given-names>A</given-names></name><name><surname>Ufer</surname> <given-names>F</given-names></name><name><surname>Flockerzi</surname> <given-names>V</given-names></name><name><surname>Brück</surname> <given-names>W</given-names></name><name><surname>Pongs</surname> <given-names>O</given-names></name><name><surname>Vennekens</surname> <given-names>R</given-names></name><name><surname>Kneussel</surname> <given-names>M</given-names></name><name><surname>Freichel</surname> <given-names>M</given-names></name><name><surname>Merkler</surname> <given-names>D</given-names></name><name><surname>Friese</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis</article-title><source>Nature Medicine</source><volume>18</volume><fpage>1805</fpage><lpage>1811</lpage><pub-id pub-id-type="doi">10.1038/nm.3015</pub-id><pub-id pub-id-type="pmid">23160238</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schattling</surname> <given-names>B</given-names></name><name><surname>Engler</surname> <given-names>JB</given-names></name><name><surname>Volkmann</surname> <given-names>C</given-names></name><name><surname>Rothammer</surname> <given-names>N</given-names></name><name><surname>Woo</surname> <given-names>MS</given-names></name><name><surname>Petersen</surname> <given-names>M</given-names></name><name><surname>Winkler</surname> <given-names>I</given-names></name><name><surname>Kaufmann</surname> <given-names>M</given-names></name><name><surname>Rosenkranz</surname> <given-names>SC</given-names></name><name><surname>Fejtova</surname> <given-names>A</given-names></name><name><surname>Thomas</surname> <given-names>U</given-names></name><name><surname>Bose</surname> <given-names>A</given-names></name><name><surname>Bauer</surname> <given-names>S</given-names></name><name><surname>Träger</surname> <given-names>S</given-names></name><name><surname>Miller</surname> <given-names>KK</given-names></name><name><surname>Brück</surname> <given-names>W</given-names></name><name><surname>Duncan</surname> <given-names>KE</given-names></name><name><surname>Salinas</surname> <given-names>G</given-names></name><name><surname>Soba</surname> <given-names>P</given-names></name><name><surname>Gundelfinger</surname> <given-names>ED</given-names></name><name><surname>Merkler</surname> <given-names>D</given-names></name><name><surname>Friese</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bassoon proteinopathy drives neurodegeneration in multiple sclerosis</article-title><source>Nature Neuroscience</source><volume>22</volume><fpage>887</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0385-4</pub-id><pub-id pub-id-type="pmid">31011226</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Shaposhnykov</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>scriptcalcium/PGC1alpha</data-title><source>Github</source><version designator="0.1">0.1</version><ext-link ext-link-type="uri" xlink:href="https://github.com/scriptcalcium/">https://github.com/scriptcalcium/</ext-link></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siffrin</surname> <given-names>V</given-names></name><name><surname>Birkenstock</surname> <given-names>J</given-names></name><name><surname>Luchtman</surname> <given-names>DW</given-names></name><name><surname>Gollan</surname> <given-names>R</given-names></name><name><surname>Baumgart</surname> <given-names>J</given-names></name><name><surname>Niesner</surname> <given-names>RA</given-names></name><name><surname>Griesbeck</surname> <given-names>O</given-names></name><name><surname>Zipp</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>FRET based ratiometric ca(2+) imaging to investigate immune-mediated neuronal and axonal damage processes in experimental autoimmune encephalomyelitis</article-title><source>Journal of Neuroscience Methods</source><volume>249</volume><fpage>8</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.jneumeth.2015.04.005</pub-id><pub-id pub-id-type="pmid">25864804</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephenson</surname> <given-names>E</given-names></name><name><surname>Nathoo</surname> <given-names>N</given-names></name><name><surname>Mahjoub</surname> <given-names>Y</given-names></name><name><surname>Dunn</surname> <given-names>JF</given-names></name><name><surname>Yong</surname> <given-names>VW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Iron in multiple sclerosis: roles in neurodegeneration and repair</article-title><source>Nature Reviews Neurology</source><volume>10</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.118</pub-id><pub-id pub-id-type="pmid">25002107</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tallantyre</surname> <given-names>EC</given-names></name><name><surname>Bø</surname> <given-names>L</given-names></name><name><surname>Al-Rawashdeh</surname> <given-names>O</given-names></name><name><surname>Owens</surname> <given-names>T</given-names></name><name><surname>Polman</surname> <given-names>CH</given-names></name><name><surname>Lowe</surname> <given-names>JS</given-names></name><name><surname>Evangelou</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis</article-title><source>Multiple Sclerosis Journal</source><volume>16</volume><fpage>406</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1177/1352458510364992</pub-id><pub-id pub-id-type="pmid">20215480</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vafai</surname> <given-names>SB</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mitochondrial disorders as windows into an ancient organelle</article-title><source>Nature</source><volume>491</volume><fpage>374</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1038/nature11707</pub-id><pub-id pub-id-type="pmid">23151580</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>Ggplot2: Elegant Graphics for Data Analysis</source><publisher-loc>New York, United States</publisher-loc><publisher-name>Springer-Verlag</publisher-name></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname> <given-names>ME</given-names></name><name><surname>Nijland</surname> <given-names>PG</given-names></name><name><surname>Drexhage</surname> <given-names>JA</given-names></name><name><surname>Gerritsen</surname> <given-names>W</given-names></name><name><surname>Geerts</surname> <given-names>D</given-names></name><name><surname>van Het Hof</surname> <given-names>B</given-names></name><name><surname>Reijerkerk</surname> <given-names>A</given-names></name><name><surname>de Vries</surname> <given-names>HE</given-names></name><name><surname>van der Valk</surname> <given-names>P</given-names></name><name><surname>van Horssen</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex</article-title><source>Acta Neuropathologica</source><volume>125</volume><fpage>231</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1007/s00401-012-1052-y</pub-id><pub-id pub-id-type="pmid">23073717</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname> <given-names>ME</given-names></name><name><surname>Schumacher</surname> <given-names>AM</given-names></name><name><surname>Mahler</surname> <given-names>CF</given-names></name><name><surname>Bewersdorf</surname> <given-names>JP</given-names></name><name><surname>Lehmitz</surname> <given-names>J</given-names></name><name><surname>Scheiter</surname> <given-names>A</given-names></name><name><surname>Sánchez</surname> <given-names>P</given-names></name><name><surname>Williams</surname> <given-names>PR</given-names></name><name><surname>Griesbeck</surname> <given-names>O</given-names></name><name><surname>Naumann</surname> <given-names>R</given-names></name><name><surname>Misgeld</surname> <given-names>T</given-names></name><name><surname>Kerschensteiner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Calcium influx through Plasma-Membrane nanoruptures drives axon degeneration in a model of multiple sclerosis</article-title><source>Neuron</source><volume>101</volume><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.12.023</pub-id><pub-id pub-id-type="pmid">30686733</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname> <given-names>S</given-names></name><name><surname>Salazar</surname> <given-names>G</given-names></name><name><surname>San Martin</surname> <given-names>A</given-names></name><name><surname>Ahmad</surname> <given-names>M</given-names></name><name><surname>Patrushev</surname> <given-names>N</given-names></name><name><surname>Hilenski</surname> <given-names>L</given-names></name><name><surname>Nazarewicz</surname> <given-names>RR</given-names></name><name><surname>Ma</surname> <given-names>M</given-names></name><name><surname>Ushio-Fukai</surname> <given-names>M</given-names></name><name><surname>Alexander</surname> <given-names>RW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PGC-1 alpha serine 570 phosphorylation and GCN5-mediated acetylation by angiotensin II drive catalase down-regulation and vascular hypertrophy</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>2474</fpage><lpage>2487</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.065235</pub-id><pub-id pub-id-type="pmid">19940161</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasuda</surname> <given-names>R</given-names></name><name><surname>Nimchinsky</surname> <given-names>EA</given-names></name><name><surname>Scheuss</surname> <given-names>V</given-names></name><name><surname>Pologruto</surname> <given-names>TA</given-names></name><name><surname>Oertner</surname> <given-names>TG</given-names></name><name><surname>Sabatini</surname> <given-names>BL</given-names></name><name><surname>Svoboda</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Imaging calcium concentration dynamics in small neuronal compartments</article-title><source>Science Signaling</source><volume>2004</volume><elocation-id>pl5</elocation-id><pub-id pub-id-type="doi">10.1126/stke.2192004pl5</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>L</given-names></name><name><surname>Kleiner</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Sah</surname> <given-names>R</given-names></name><name><surname>Gupta</surname> <given-names>RK</given-names></name><name><surname>Banks</surname> <given-names>AS</given-names></name><name><surname>Cohen</surname> <given-names>P</given-names></name><name><surname>Khandekar</surname> <given-names>MJ</given-names></name><name><surname>Boström</surname> <given-names>P</given-names></name><name><surname>Mepani</surname> <given-names>RJ</given-names></name><name><surname>Laznik</surname> <given-names>D</given-names></name><name><surname>Kamenecka</surname> <given-names>TM</given-names></name><name><surname>Song</surname> <given-names>X</given-names></name><name><surname>Liedtke</surname> <given-names>W</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Puigserver</surname> <given-names>P</given-names></name><name><surname>Griffin</surname> <given-names>PR</given-names></name><name><surname>Clapham</surname> <given-names>DE</given-names></name><name><surname>Spiegelman</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TRPV4 is a regulator of adipose oxidative metabolism, inflammation, and energy homeostasis</article-title><source>Cell</source><volume>151</volume><fpage>96</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.08.034</pub-id><pub-id pub-id-type="pmid">23021218</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>LG</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>He</surname> <given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS: A Journal of Integrative Biology</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>B</given-names></name><name><surname>Liao</surname> <given-names>Z</given-names></name><name><surname>Locascio</surname> <given-names>JJ</given-names></name><name><surname>Lesniak</surname> <given-names>KA</given-names></name><name><surname>Roderick</surname> <given-names>SS</given-names></name><name><surname>Watt</surname> <given-names>ML</given-names></name><name><surname>Eklund</surname> <given-names>AC</given-names></name><name><surname>Zhang-James</surname> <given-names>Y</given-names></name><name><surname>Kim</surname> <given-names>PD</given-names></name><name><surname>Hauser</surname> <given-names>MA</given-names></name><name><surname>Grünblatt</surname> <given-names>E</given-names></name><name><surname>Moran</surname> <given-names>LB</given-names></name><name><surname>Mandel</surname> <given-names>SA</given-names></name><name><surname>Riederer</surname> <given-names>P</given-names></name><name><surname>Miller</surname> <given-names>RM</given-names></name><name><surname>Federoff</surname> <given-names>HJ</given-names></name><name><surname>Wüllner</surname> <given-names>U</given-names></name><name><surname>Papapetropoulos</surname> <given-names>S</given-names></name><name><surname>Youdim</surname> <given-names>MB</given-names></name><name><surname>Cantuti-Castelvetri</surname> <given-names>I</given-names></name><name><surname>Young</surname> <given-names>AB</given-names></name><name><surname>Vance</surname> <given-names>JM</given-names></name><name><surname>Davis</surname> <given-names>RL</given-names></name><name><surname>Hedreen</surname> <given-names>JC</given-names></name><name><surname>Adler</surname> <given-names>CH</given-names></name><name><surname>Beach</surname> <given-names>TG</given-names></name><name><surname>Graeber</surname> <given-names>MB</given-names></name><name><surname>Middleton</surname> <given-names>FA</given-names></name><name><surname>Rochet</surname> <given-names>JC</given-names></name><name><surname>Scherzer</surname> <given-names>CR</given-names></name><collab>Global PD Gene Expression (GPEX) Consortium</collab></person-group><year iso-8601-date="2010">2010</year><article-title>PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease</article-title><source>Science Translational Medicine</source><volume>2</volume><elocation-id>52ra73</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3001059</pub-id><pub-id pub-id-type="pmid">20926834</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorova</surname> <given-names>LD</given-names></name><name><surname>Popkov</surname> <given-names>VA</given-names></name><name><surname>Plotnikov</surname> <given-names>EY</given-names></name><name><surname>Silachev</surname> <given-names>DN</given-names></name><name><surname>Pevzner</surname> <given-names>IB</given-names></name><name><surname>Jankauskas</surname> <given-names>SS</given-names></name><name><surname>Babenko</surname> <given-names>VA</given-names></name><name><surname>Zorov</surname> <given-names>SD</given-names></name><name><surname>Balakireva</surname> <given-names>AV</given-names></name><name><surname>Juhaszova</surname> <given-names>M</given-names></name><name><surname>Sollott</surname> <given-names>SJ</given-names></name><name><surname>Zorov</surname> <given-names>DB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mitochondrial membrane potential</article-title><source>Analytical Biochemistry</source><volume>552</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2017.07.009</pub-id><pub-id pub-id-type="pmid">28711444</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.61798.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Harvey</surname><given-names>Brandon K</given-names></name><role>Reviewing Editor</role><aff><institution>NIDA/NIH</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The study by Rosenkranz and colleagues explores the relationship between mitochondrial activity and neurodegeneration associated with inflammatory lesions in the central nervous system, a scientifically and clinically important topic with direct relevance to multiple sclerosis (MS). Their results reinforce the therapeutic potential of the transcription factor PGC1α for treating neuroinflammation associated with neurodegeneration, specifically in multiple sclerosis.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Enhancing mitochondrial activity in neurons protects against neurodegeneration in CNS inflammation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Satyajit Rath as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>The study by Rosenkranz and colleagues explores the relationship between mitochondrial activity and neurodegeneration in inflammatory CNS lesions, a scientifically and clinically important topic with direct relevance to multiple sclerosis. They found transcription of mitochondrial genes related to the electron transport chain (ETC) are decreased in motor neurons derived from EAE animals in line with a reduced complex IV activity that is observed throughout the spinal gray matter in EAE. They link these changes to the transcription factor PGC1α. Manipulating PGC1α levels modulated mitochondrial function and the pathological features of an EAE model in a manner consistent with PGC1α having therapeutic potential for neuroinflammation associated with neurodegeneration, specifically in multiple sclerosis.</p><p>Essential revisions:</p><p>1) The majority of lesions in most EAE models are located lumbar spinal cord and the clinical score indicates that this is also the case in this paper. However, the entire analysis was performed in the cervical spinal cord. As a result of this, the changes observed would be mostly distal to the most heavily inflamed areas of the spinal cord. It would be informative and important for the interpretation of data to know whether the key findings of the study and in particular the beneficial effects of Pgc -1α overexpression on complex IV activity and neuronal survival (in the absence of an effect on the local inflammatory reaction) are also present in the lumbar spinal cord.</p><p>2) The identification of Pgc1α as a therapeutic target is derived from the reduced expression of Pgc-1α-dependent ETC genes in the EAE spinal cord (Figure 2). If possible, it would be helpful to show that (at least some of) these changes to neuronal gene expression are reversed by Pgc-1α overexpression in the EAE spinal cord and provide further support for PGC1α as a therapeutic approach to MS.</p><p>3) NeuN is used a marker for visualizing neurons, but the expression of NeuN can be modulated, particularly under inflammatory conditions. An additional reference marker should be considered before concluding differences between EAE and control animals.</p><p>4) Both conditional Pgc-1α deficient and Pgc-1α overexpressing mice show an altered density of neurons in the GM and the ventral spinal cord in the context of EAE, confirm the neuronal densities in these areas do not differ in the corresponding age-matched healthy mice.</p><p>5) In Figure 3E, the images are labeled as &quot;representative&quot; but do not appear to represent the data from hPNC. A quick analysis of the images suggests 5-8 fold increase (not the 1.5 -2.5 indicated by the MFI). Are images from hPNC or cPNC? In the graph, it appears there may be a bimodal distribution of cells for hPNC from PGC1α group (possibly cPNC as well), is there any technical reason that might account for clustering? For cPNC, it appears there are a few outliers. Why was t-test used not ANOVA?</p><p>6) The authors claim that there is no difference in immune response between wild type and PGC-1αTT mice, however in Figure 5D, the micrograph for IBA does not support this claim, and appears to contradict the graph. There is clearly more IBA in the chosen tissue section from the PGC-1αTT mice, compared to wild type, but the graph suggests a decrease (although does not appear to be significant).</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Satyajit Rath as the Senior Editor.</p><p>Essential revision:</p><p>The manuscript has been improved but there is a remaining issue that need to be addressed before acceptance, as outlined below:</p><p>The authors address the appropriateness of the model by referring to a study showing that clinical scores correlate better with cervical spinal cord lesions in EAE, however, they did not incorporate this reference nor address the concern of approach in the revised manuscript. Given this was part of essential revision, the authors should consider addressing choice of focusing on the cervical region of SC rather than lumbar in the manuscript proper.</p><p>Other concerns are adequately addressed.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.61798.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The majority of lesions in most EAE models are located lumbar spinal cord and the clinical score indicates that this is also the case in this paper. However, the entire analysis was performed in the cervical spinal cord. As a result of this, the changes observed would be mostly distal to the most heavily inflamed areas of the spinal cord. It would be informative and important for the interpretation of data to know whether the key findings of the study and in particular the beneficial effects of Pgc -1α overexpression on complex IV activity and neuronal survival (in the absence of an effect on the local inflammatory reaction) are also present in the lumbar spinal cord.</p></disp-quote><p>We thank the reviewers for their comment and welcome the opportunity to explain our rationale by first drawing their attention to previous findings, in which it was shown that clinical scores correlate better with cervical spinal cord lesions in EAE (Philippe et al., 2017). Moreover, in our own previous studies (Friese et al., 2007; Schattling et al., 2012, 2019; Rosenkranz et al., 2020) we characterized immune cell infiltration, demyelination and neuronal loss in the cervical spinal cord that also showed robust correlation with the clinical phenotype. While we agree that the lesions in EAE are similarly present in the lumbar spinal cord, out of the above reasons we believe that our data sufficiently back our interpretations. We hope that the reviewers regard our approach as appropriate.</p><disp-quote content-type="editor-comment"><p>2) The identification of Pgc1α as a therapeutic target is derived from the reduced expression of Pgc-1α-dependent ETC genes in the EAE spinal cord (Figure 2). If possible, it would be helpful to show that (at least some of) these changes to neuronal gene expression are reversed by Pgc-1α overexpression in the EAE spinal cord and provide further support for PGC1α as a therapeutic approach to MS.</p></disp-quote><p>We thank the reviewer for pointing this out and agree that this would be an interesting analysis. Thus, we performed a qPCR analysis of the PGC-1α-regulated ETC genes, which we previously detected to be downregulated in EAE, in wild-type and <italic>Thy1</italic>-Ppargc1a primary hippocampal neurons. Importantly, we could observe a significant increase of 11 out of 17 analyzed genes (new Figure 3A), supporting a therapeutic approach. We agree that analysis of these genes in neurons during EAE would have been a nice addition, however due to Corona restrictions we were limited in our breeding capacity and could not cross our <italic>Chat-L10-eGFP</italic>Bactrap mice to <italic>Ppargc1a</italic>-overexpressing animals. However, we believe that our new data set sufficiently supports our claims.</p><disp-quote content-type="editor-comment"><p>3) NeuN is used a marker for visualizing neurons, but the expression of NeuN can be modulated, particularly under inflammatory conditions. An additional reference marker should be considered before concluding differences between EAE and control animals.</p></disp-quote><p>We agree with the reviewer that NeuN staining can be diminished in EAE, thereby compromising our analysis. Following the reviewer’s suggestion, we performed stainings with HuC/HuD, an alternative neuronal marker that now served us as reference for normalization of neuronal counts. By doing so, we revealed that the reduction of COX activity at day 30 was partly driven by neuronal loss, which is now shown in the new Figure 1G. Furthermore, we added an analysis of the EAE tissue from <italic>Thy1</italic>-Ppargc1a vs. wild-type and <italic>Ppargc1a</italic><sup>flx/flx</sup> × <italic>Eno2</italic><sup>cre+</sup> vs. <italic>Ppargc1a</italic><sup>flx/flx</sup> at day 40 post immunization by using HuC/HuD staining as neuronal marker. In comparison to the NeuN staining we detected higher overall neuronal numbers with the HuC/HuD staining in all tissues, however the significant differences between <italic>Thy1</italic>-Ppargc1a vs. wild-type and <italic>Ppargc1a</italic><sup>flx/flx</sup> × <italic>Eno2</italic><sup>cre+</sup> vs. <italic>Ppargc1a</italic><sup>flx/flx</sup> were not affected by using the different stainings (new Figure 5—figure supplement 1G and I).</p><disp-quote content-type="editor-comment"><p>4) Both conditional Pgc-1α deficient and Pgc-1α overexpressing mice show an altered density of neurons in the GM and the ventral spinal cord in the context of EAE, confirm the neuronal densities in these areas do not differ in the corresponding age-matched healthy mice.</p></disp-quote><p>We agree that this is an important control as the initial numbers of neurons could influence our EAE outcome measures. Therefore, we performed stainings and analyses of healthy <italic>Ppargc1a</italic><sup>flx/flx</sup> × <italic>Eno2</italic><sup>cre+</sup> vs. <italic>Ppargc1a</italic><sup>flx/flx</sup> and <italic>Thy1</italic>-Ppargc1a vs. wild-type animals and could confirm that the different genotypes did not differ in neuronal counts in the GM or VH. This is now shown in the new Figure 5—figure supplement 1H and J.</p><disp-quote content-type="editor-comment"><p>5) In Figure 3E, the images are labeled as &quot;representative&quot; but do not appear to represent the data from hPNC. A quick analysis of the images suggests 5-8 fold increase (not the 1.5 -2.5 indicated by the MFI). Are images from hPNC or cPNC? In the graph, it appears there may be a bimodal distribution of cells for hPNC from PGC1α group (possibly cPNC as well), is there any technical reason that might account for clustering? For cPNC, it appears there are a few outliers. Why was t-test used not ANOVA?</p></disp-quote><p>We thank the reviewer for this advice and replaced the representative image of the WT hPNC (new Figure 3F). As <italic>Thy1</italic> expression shows heterogeneity this might be the explanation of the detected range of TMRE in <italic>Thy1</italic>-Ppargc1a mice. However, as indicated in the statistical methods we performed an outlier analysis and none of the data points shown were detected as outlier in our analysis. T-tests were used to compare the two groups of interest with each other – <italic>Thy1</italic>-Ppargc1a vs. wild-type.</p><disp-quote content-type="editor-comment"><p>6) The authors claim that there is no difference in immune response between wild type and PGC-1αTT mice, however in Figure 5D, the micrograph for IBA does not support this claim, and appears to contradict the graph. There is clearly more IBA in the chosen tissue section from the PGC-1αTT mice, compared to wild type, but the graph suggests a decrease (although does not appear to be significant).</p></disp-quote><p>We agree that the figure was not ideally chosen and replaced the representative image of the Iba1 stainings in Figure 5D.</p><p>References:</p><p>Philippe A, Quenault A, Martinez S, Lizarrondo D, Gauberti M, Defer G (2017) Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin. PNAS 114:6116–6121.Rosenkranz SC, Shaposhnykov A, Schnapauff O, Epping L, Vieira V, Heidermann K, Schattling B, Tsvilovskyy V, Liedtke W, Meuth SG, Freichel M, Gelderblom M, Friese MA (2020) TRPV4-Mediated Regulation of the Blood Brain Barrier Is Abolished During Inflammation. Front Cell Dev Bio 8:1–9.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Essential revision:</p><p>The manuscript has been improved but there is a remaining issue that need to be addressed before acceptance, as outlined below:</p><p>The authors address the appropriateness of the model by referring to a study showing that clinical scores correlate better with cervical spinal cord lesions in EAE, however, they did not incorporate this reference nor address the concern of approach in the revised manuscript. Given this was part of essential revision, the authors should consider addressing choice of focusing on the cervical region of SC rather than lumbar in the manuscript proper.</p></disp-quote><p>We thank the reviewers for their positive and encouraging feedback and apologize for the oversight not addressing this point in our manuscript. We now included the following sentence in the Materials and methods section and cited the respective reference: “Cervical spinal cord was used as it was shown that clinical scores correlate better with cervical than lumbar spinal cord lesions in EAE (Fournier et al., 2017).”</p></body></sub-article></article>